{"title": "Immunotherapy and gene therapy as novel treatments for cancer", "author": "Martha Montserrat Rangel-Sosa; Estuardo Aguilar-C\u00f3rdova; Augusto Rojas-Mart\u00ednez", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687866/", "hostname": "ncbi.nlm.nih.gov", "description": "The immune system interacts closely with tumors during the disease development and progression to metastasis. The complex communication between the immune system and the tumor cells can prevent or promote tumor growth. New therapeutic approaches harnessing ...", "sitename": "PubMed Central (PMC)", "date": "2017-01-01", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Learn more:\n[PMC Disclaimer](/pmc/about/disclaimer/)| [PMC Copyright Notice](/pmc/about/copyright/) [10.25100/cm.v48i3.2997](//doi.org/10.25100%2Fcm.v48i3.2997) [29213157](https://pubmed.ncbi.nlm.nih.gov/29213157) [Spanish](#s1).\nImmunotherapy and gene therapy as novel treatments for cancer\nInmunoterapia y terapia g\u00e9nica como nuevos tratamientos contra el c\u00e1ncer\nAbstract\nThe immune system interacts closely with tumors during the disease development and progression to metastasis. The complex communication between the immune system and the tumor cells can prevent or promote tumor growth. New therapeutic approaches harnessing protective immunological mechanisms have recently shown very promising results. This is performed by blocking inhibitory signals or by activating immunological effector cells directly. Immune checkpoint blockade with monoclonal antibodies directed against the inhibitory immune receptors CTLA-4 and PD-1 has emerged as a successful treatment approach for patients with advanced melanoma. Ipilimumab is an anti-CTLA-4 antibody which demonstrated good results when administered to patients with melanoma. Gene therapy has also shown promising results in clinical trials. Particularly, Herpes simplex virus (HSV)-mediated delivery of the HSV thymidine kinase (TK) gene to tumor cells in combination with ganciclovir (GCV) may provide an effective suicide gene therapy for destruction of glioblastomas, prostate tumors and other neoplasias by recruiting tumor-infiltrating lymphocytes into the tumor. The development of new treatment strategies or combination of available innovative therapies to improve cell cytotoxic T lymphocytes trafficking into the tumor mass and the production of inhibitory molecules blocking tumor tissue immune-tolerance are crucial to improve the efficacy of cancer therapy.\nResumen\nEl sistema inmune interact\u00faa \u00edntimamente con los tumores durante el proceso del desarrollo de la enfermedad y su progresi\u00f3n a met\u00e1stasis. Esta compleja comunicaci\u00f3n entre el sistema inmune y las c\u00e9lulas tumorales puede prevenir o promover el crecimiento del tumor. Los nuevos enfoques terap\u00e9uticos que aprovechan los mecanismos inmunol\u00f3gicos, ya sea por el bloqueo de se\u00f1ales inhibitorias o por la activaci\u00f3n directa de c\u00e9lulas efectoras, han mostrado resultados prometedores. El bloqueo de puntos de control inmunol\u00f3gicos immune-checkpoints con anticuerpos monoclonales dirigidos contra receptores que normalmente inhiben el sistema inmune, como CTLA-4 o PD-1, ha resultado ser un tratamiento exitoso para pacientes con melanoma avanzado. El f\u00e1rmaco ipilimumab es un anticuerpo anti-CTLA-4 que ha demostrado buenos resultados terap\u00e9uticos en pacientes con melanoma. Por otro lado, la terapia g\u00e9nica tambi\u00e9n ha mostrado resultados prometedores en ensayos cl\u00ednicos. En especial, la administraci\u00f3n de la enzima timidina quinasa del virus Herpes simplex (HSV-TK) en combinaci\u00f3n con el f\u00e1rmaco ganciclovir (GCV) ha mostrado ser una terapia suicida muy efectiva para la destrucci\u00f3n de diferentes neoplasias incluyendo glioblastomas y tumores prost\u00e1ticos, por un mecanismo que involucra el reclutamiento de linfocitos infiltrantes de tumor. Es importante la b\u00fasqueda de nuevas estrategias o la combinaci\u00f3n de terapias innovadoras, con el fin de involucrar tanto la atracci\u00f3n de linfocitos citot\u00f3xicos as\u00ed como el empleo de mol\u00e9culas que inhiban la inmunotolerancia del tejido tumoral para mejorar la eficiencia de los tratamientos contra el c\u00e1ncer.\nIntroduction\nCancer progression is accompanied by a strong suppression of the immune system (IS), which interferes with effective antitumor response and diminishes tumor eradication\n[\n1\n](#B1). The immune-surveillance evasion occurs, in part, due to the fact that the tumor microenvironment inhibits T cell proliferation and attracts immune-suppressor cells [\n2\n](#B2).\nA better knowledge of the interaction between the tumor and the IS has allowed the development of specific therapies designed to improve patient\u00b4s immune response. Tumor immunotherapy has two strategies: attack the tumor directly or activate the IS by the use of cell therapies, like stimulatory agonists or the immune-checkpoint blockade\n[\n3\n](#B3); The latter has demonstrated a potential antitumoral immune response, proving to be a promising therapy [\n4\n](#B4). Another option is the use of a different approach: gene therapy, which allows modifying tumor gene expression for therapeutic purposes. For example, tumor cell transduction with \"suicide genes\" is a largely investigated strategy of anti-neoplastic gene therapy [\n5\n](#B5).\nThis article reviews the use of immune-checkpoint blockade and suicide gene therapy as different alternatives for cancer therapy and analyzes the possible synergic effects that can be reach with the combination of this both therapies.\n1. Cancer and immune system\nThe IS interacts intimately with the tumors during the process of disease development and its progression to metastasis (tumoral immunology)\n[\n6\n](#B6). It also respond to cancer by recognizing and eliminating the abnormal cells (immuno-surveillance) [\n7\n](#B7). However, some resistant cells can evade this control (immunoediting)\n[\n8\n](#B8) reducing their immunogenicity [\n9\n](#B9) and promoting malignant growth [\n7\n](#B7).\nTumor cells change their surface markers recurrently.. For example, they express tumor-associated antigens (TAA)\n[\n10\n](#B10) or reduce the expression of the major histocompatibility complex (MHC) class I. This can lead to the activation of the innate immune response cells, such as natural killer (NK) cells [\n10\n](#B10). Macrophages and neutrophils may attack the tumor cells and stimulate the cytotoxic T lymphocytes (CTL), the antigen-presenting cell (APC) and the NK cells. In contrast, inflammatory cells produce growth factors and angiogenesis-stimulating growth factors promoting tumor growht\n[\n11\n](#B11).\nIn the adaptive response, the processed TAA are presented by the MHC class I and II molecules from APCs to the specific receptors of T CD8+ and CD4+ cells respectively for their activation\n[\n10\n](#B10)\n,\n[\n12\n](#B12). The CD8+ T lymphocytes are considered the main antitumor effector cells [\n13\n](#B13). Once activated, they mediate the lysis of tumor cells [\n10\n](#B10). Among the CD4+ T cells, the Th1 are responsible for cellular immunity: they secrete interleukine (IL)-2, TNF\u03b1 and interpheron-\u03b3 (IFN-\u03b3), promote the macrophage\u00b4s cytotoxic activity and induce the overexpression of MHC I and III in the APC. In contrast, the Th2 cells express IL-4, -5, -10 and -13, inducing clonal anergy, enhancing humoral immunity and regulating macrophage activity [\n13\n](#B13). On the other hand, the regulatory T (Treg) cells help to reduce inflammation by the production of TGF-\u03b2, IL-35 e IL-10 [\n10\n](#B10). The tumor cells can secrete chemokines as CCL22 which recruit Treg cells to supress the effector function of T cells and decreasing the immune response [\n10\n](#B10).\nTumors can also deregulate the IS by altering a complex balance between activating and inhibitory signals (checkpoints) in different pathways that regulate the function of T cells\n[\n7\n](#B7).\n2. Regulatory T cells\nTreg cells are relevant to the maintenance of the immunological homeostasis: they preserve the tolerance to self-antigens, prevent the autoimmune diseases, modulate the development of an immune response and favor the escape of tumor cells from immune control\n[\n14\n](#B14)\n,\n[\n15\n](#B15). The best-characterized subpopulation expresses CD4, CD25 and Foxp3. Treg can suppress different cells such as CD4+ and CD8+ T lymphocytes, natural killer T cells, dendritic cells (DC), monocytes/macrophages, B lymphocytes and NK cells [\n14\n](#B14).\nBecause Treg suppresses the immune response against self-antigens\n[\n8\n](#B8)\n,\n[\n16\n](#B16), it is postulated that TAA may induce an increase in the number of intratumoral Treg cells in several neoplasms, including colorectal cancer (CRC), facilitating tumor immunotolerance [\n8\n](#B8)\n,\n[\n17\n](#B17). The accumulation of Treg in tumors is explained by several mechanisms, such as the conversion of CD4+ T cells to Treg in response to membrane-bound TGF-\u03b2, the recruitment of Tregs by chemokines as CCL17, CCL22 and CCL28 and tumor secretion of VEGF-A in response to hypoxia, which inhibits DC maturation. Immature DCs express TGF-\u03b2 favoring the conversion of CD4 + T cells to Treg [\n18\n](#B18).\nThe most frequents TAA are own-antigens subexpressed in normal cells but highly expressed in tumor cells\n[\n18\n](#B18). One of the best known is the carcinoembryonic antigen (CEA) which is highly expressed in CRC [\n18\n](#B18); the CEA is recognized as a self-antigen by the Tregs [\n19\n](#B19), causing a poor immune response to tumor cells. In ovarian, breast, pancreatic, stomach and liver cancers, an increase in Treg lymphocytes in the tumor is associated with a worse prognosis [\n17\n](#B17). The use of these cells as targets may benefit the therapeutic strategies against cancer [\n8\n](#B8).\n2.1 Action mechanisms of the Treg cells\nThe Treg lymphocytes have four main mechanisms of action to regulate the immune response\n[Fig. 1](/pmc/articles/PMC5687866/figure/f1/). The first is suppression by inhibitory cytokines, which include IL-3, IL-10 and TGF-\u03b2 [\n18\n](#B18), [\n20\n](#B20)\n. The second is suppression by cytolysis. Tregs may induce cytolysis of B cells through the production of granzyme B. These cells may also exert a cytolytic effect to CD8+ T lymphocytes and NK cells by granzyme-B-dependent and perforin-dependent killing mechanisms, or by the aTRAIL-DR5 [\n20\n](#B20)\n-\n[\n22\n](#B22) pathway [\n20\n](#B20)\n-\n[\n22\n](#B22). The third mechanism is the suppression by metabolic alterations that affect the activity of molecules such as CD25 (IL-2 receptor), cyclic AMP (cAMP), CD39, CD73 and adenosine 2A receptor (A2AR) [\n20\n](#B20). The fourth mechanism consists on the suppression of the maturation and/or function of DC. This includes pathways such as the lymphocyte-activation gene-3 (LAG3) or the interaction between cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and CD80/86, which induces the enzyme indoleamine 2,3-dioxygenase (IDO), an immunosuppressive molecule generated by DC [\n10\n](#B10)\n,\n[\n20\n](#B20). The blocking of these immunosuppressive mechanisms could increase the function of T cells and generate a more effective clinical response [\n8\n](#B8)\n,\n[\n20\n](#B20).\n2.2 Regulation of immune-checkpoints by Treg cells\nIn the case of T cells, the amplitude and quality of the response after recognition of an antigen is regulated by a balance between costimulatory and inhibitory signals (immune-checkpoint)\n[\n4\n](#B4). In order to increase the effector function of tumor-infiltrating T cells, the immunosuppressive signals can be inhibited. There has been a greater clinical success with this strategy in the treatment of several types of cancer, such as melanoma and lung cancer [\n6\n](#B6). Some molecules that act as immune-checkpoints, such as CTLA-4 receptor and programmed cell death protein 1 (PD-1), are expressed on Treg lymphocytes and tumor-infiltrating effector T cells [\n15\n](#B15).\n2.3 Cancer immune-checkpoints\nAs previously mentioned, the activation and inhibition of different receptors regulate the balance between immune response and immunotolerance\n[\n23\n](#B23)\n,\n[\n24\n](#B24), which is important for complete activation and effector function of T cells [\n25\n](#B25). The antibody therapy against negative immunological regulators has shown success in antineoplastic therapy [\n23\n](#B23)\n,\n[\n25\n](#B25), because it increases the potential of the antitumor immune response.\nIt has been demonstrated that tumors use some immunological control pathways as a mechanism of immune resistance\n[\n4\n](#B4), e.g. increasing the expression of the checkpoint proteins decreases the function of T cells. Examples of immunological checkpoints are PD-1, CTLA-4, LAG-3, T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), among others [\n26\n](#B26).\nAntitumor antibodies that block immune-checkpoints are directed against lymphocyte receptors or their ligands\n[\n27\n](#B27)\n[Table 1](/pmc/articles/PMC5687866/table/t1/). Two immune-checkpoints widely studied in the clinical context of cancer immunotherapy are CTLA-4 and PD-1. Both are inhibitory receptors that regulate the immune response [\n27\n](#B27). Although inhibition of control points seems to be successful in the treatment of some cancers, adverse events are associated, in particular autoimmune responses affecting organs such as the colon, skin, some endocrine glands, liver, etc [\n26\n](#B26).\nTable 1\n|Target||Biological function||Antibodie||Clinical situation|\n|CTLA-4||Inhibitory receptor||Ipilimumab||Approved by the FDA for melanoma. Phase IV trials for melanoma and metastatic renal cell cancer. Phase III trials for stomach / esophagus cancer, small cell and non-small cell lung cancer, renal carcinoma, pleural mesothelioma, metastatic squamous cell carcinoma of the head and neck, prostate cancer, ocular melanoma.|\n|Tremelimumab||Tested in phase III trials for melanoma, head and neck cancer, small and non-small cell lung cancer, urothelial cancer.|\n|PD-1||Inhibitory receptor||Nivolumab||FDA approved for melanoma, renal carcinoma, non-small cell lung cancer. Phase IV trials for advanced metastatic renal carcinoma and metastatic melanoma. Phase III trials for small cell and non-small cell lung cancer, stomach/esophagus cancer, melanoma, mesothelioma, hepatocellular carcinoma, multiple myeloma, urothelial cancer, gastric cancer.|\n|Pembrolizumab||FDA approved for melanoma, non-small cell lung cancer. Phase III trials for melanoma and small and non-small cell lung cancer.|\n|Pidilizumab||Phase I/II trials for lymphoma, multiple myeloma, pancreatic cancer.|\n|PD-L1||Programmed death-ligand 1||BMS-936559||Phase I trials for melanoma.|\n|Atezolizumab||Phase III trials for small cell and non-small cell lung cancer, triple negative breast cancer, urinary tract cancer, renal cancer, ovarian cancer, colorectal cancer, melanoma.|\n|LAG3||Inhibitory receptor||IMP321||Phase I / II trials for breast adenocarcinoma, renal carcinoma, melanoma, pancreatic neoplasms.|\n|B7-H3||Inhibitory ligand||Enoblituzumab||Phase I trials for various types of cancer.|\nCTLA-4: Cytotoxic T-Lymphocyte Antigen 4;\nLAG3: Lymphocyte-activation gene 3;\nPD-1: Programmed cell death protein 1;\nPD-L1: Programmed death-ligand 1.\n2.4 CTLA-4\nThe CTLA-4 receptor is the first immune-checkpoint used as clinical target\n[\n28\n](#B28). CTLA-4 is a member of the immunoglobulin superfamily CD28:B7. It is normally expressed at low levels on the surface of effector T cells and Treg cells. Its function is to regulate the amplitude of the early stages activation of these kinds of cells [\n28\n](#B28). To activate a T cell, three signals are required: the antigen binding to the T cell receptor (TCR), the interaction of MHC (in human: human leukocyte antigen, HLA) with CD8 or CD4 T cell receptors, and the generation of a costimulatory signal generated by the binding of CD80(B7) to CD28 [\n12\n](#B12)\n,\n[\n29\n](#B29). Once this is completed, the CD28 pathway amplifies the TCR signaling to activate T cell proliferation. CD28 and CTLA-4 share the same ligands: CD80 (B7.1) and CD86 (B7.2), however these ligands bind to CTLA-4 with higher affinity [\n4\n](#B4)\n,\n[\n30\n](#B30), because of this, CTLA-4 counteracts the costimulatory activity of CD28 [\n4\n](#B4)\n,\n[\n31\n](#B31).\nCTLA-4 is crucial in T-cell activation. This is demonstrated by the lethal phenotype of the hyperactivated immune system in CTLA-4 knockout mice\n[\n4\n](#B4). Although CTLA-4 is expressed in activated effector CD8+ T cells, its most important physiological function is through different effects on CD4+ T cells: the activity decrease of helper T cells (Th1) and the enhancing of the immunosuppressive activity of Treg cells [\n4\n](#B4).\nIt has been proposed that CTLA-4 expression attenuates the activation of T cells by a cascade of inhibitory signals\n[Fig. 2](/pmc/articles/PMC5687866/figure/f2/), as well as by its competition with CD28 [\n30\n](#B30). Some studies suggest that the activation of protein-tyrosine phosphatase (SHP2) and protein phosphatase 2A (PP2A) counteracts the kinase signals induced by the TCR and CD28 [\n30\n](#B30). Other mechanisms, including Treg cell expansion, produce immunosuppressive cytokines such as TGF-\u03b2 and the enzyme IDO [\n32\n](#B32).\nCTLA-4 blockade can affect the intratumoral immune response by inactivating Treg tumor-infiltrating lymphocytes\n[\n33\n](#B33) which can cause an increase in the Th1-dependent immune response [\n4\n](#B4). It has also been observed that its blockade enhances the production of specific antibodies against TAA, as well as a CD4+ cellular and CD8+ specific antigen response [\n27\n](#B27).\n2.5 PD-1\nPD-1 is also a key protein in immune regulation\n[\n27\n](#B27), it acts as an immune-checkpoint and immune-therapeutic target. It is a co-inhibitory molecule expressed in stimulated T cells, as well as in Treg lymphocytes, B-activated cells and NK cells [\n27\n](#B27)\n,\n[\n31\n](#B31). PD-1 appears to play a crucial role in the modulation of T cell activity through interaction with its PD-L1 and PD-L2 ligands [\n31\n](#B31). PD-L1 is expressed in lymphoid and non-lymphoid tissues, it is activated especially in APC, DC, macrophages and B cells, but is also expressed in tumor cells that abrogate the lymphocyte response. Expression of this ligand in tumor tissue is recognized by effector T lymphocytes, which restrict their oncolytic activity to induce cancer immunotolerance [\n24\n](#B24). PD-L2 is only expressed in the APC [\n24\n](#B24).\nAfter binding to its ligand, PD-1 suppresses T cell activation by recruiting SHP-2, which dephosphorylates and inactivates Zap70, an important component in the TCR signaling pathway. As result, PD-1 inhibits T-cell proliferation and its effector functions, such as the production of IFN-\u03b3\n[\n24\n](#B24). PD-1 blockade may enhance antineoplastic immune responses by decreasing the number and suppressive activity of intratumoral Treg cells [\n4\n](#B4), in addition to increasing the proliferation of effector T cells (CD8+/HLA-DR+/Ki67+T cells), interferon-inducible T-cell alpha chemoattractant (I-TAC), IFN-\u03b3 and IL-18 [\n4\n](#B4).\n2.6 Interacciones entre CTLA-4 y PD-1\nAlthough CTLA-4 and PD-1 negatively regulate the activation of T cells by blocking the CD3/CD28 pathway, these receptors have different roles\n[\n27\n](#B27). CTLA-4 acts during the beginning of naive and memory T cells activation in lymphoid tissue, while PD-1 operates during the effector phase of T cells [Fig. 3](/pmc/articles/PMC5687866/figure/f3/)\n[\n27\n](#B27)\n,\n[\n34\n](#B34). The interaction of PD-1 with its PD-L1 ligand occurs predominantly in peripheral tissues, including tumor tissue [\n15\n](#B15)\n,\n[\n27\n](#B27)\n,\n[\n34\n](#B34).\nThere are preclinical studies that propose a combined therapy using antibodies for the blockade of both pathways simultaneously (anti-CTLA-4 plus anti-PD-1)\n[\n12\n](#B12). This dual strategy would enhance the antitumor response but it can also be expected to be more toxic [\n35\n](#B35).\n2.7 Clinical use of immune-checkpoint blockade therapy\nIpilimumab (anti-CTLA-4) is a recombinant human monoclonal antibody (IgG1 kappa immunoglobulin) approved by the Food and Drug Administration (FDA) in 2011 for the treatment of metastatic melanoma. The human monoclonal antibody nivolumab (anti-PD-1) is an IgG4 kappa immunoglobulin authorized in Japan in 2014 for the treatment of unresectable melanoma. The FDA approved the humanized monoclonal antibody pembrolizumab (IgG4 kappa immunoglobulin) against PD-1 in September 2014 and the nivolumab in December 2014, both for the treatment of advanced melanoma. In March 2015 the FDA approved nivolumab for the treatment of lung cancer\n[\n32\n](#B32).\nThere are phase II studies proving increased survival in patients with metastatic melanoma who received ipilimumab\n[\n7\n](#B7)\n,\n[\n36\n](#B36). In one study, an average survival of 10.1 months was observed in patients using ipilimumab versus 6.4 months in patients using a control peptide vaccine [\n36\n](#B36); a 5-year survival rate of 18.2% was also observed in patients with advanced melanoma treated with ipilimumab+dacarbazine versus 8.8% in patients treated with placebo+dacarbazine [\n37\n](#B37). Two phase III studies of nivolumab showed clear benefits of this agent against metastatic melanoma compared to chemotherapy, obtaining a better survival rate at one year [\n36\n](#B36). In July 2017, the Bristol-Myers Squibb biopharmaceutical announced that the FDA expanded the use of intravenously administered ipilimumab as a treatment for non-extirpable metastatic melanoma in pediatric patients of 12 years or older. In addition, in August 2017, it was announced that nivolumab was approved by the FDA for the treatment of adult and pediatric patients (over 12 years of age) with metastatic colorectal cancer who present high microsatellite instability (MSI-H) or deficiencies in the repair of damaged DNA, and who had received a treatment with fluoropyrimidines, oxaliplatin, and irinotecan. The pembrolizumab and nivolumab (FDA approved) were compared with ipilimumab, demonstrating a higher response and lower toxicity [\n36\n](#B36). In addition, it was observed that PD-1 blockade had activity in patients who did not respond to CTLA-4 blockade [\n36\n](#B36). It has been proposed that agents which inhibit PD-1 are more effective than those that inhibit PD-L1 directly (e.g. human monoclonal antibody BMS-936559) [\n38\n](#B38) because they can inhibit both ligands (PD-L1 and PD-L2) simultaneously [\n38\n](#B38).\nIn 2015, the safety and efficacy of nivolumab and ipilimumab were assessed separately and compared vs nivolumab+ipilimimab as a novel combined therapy (recorded as CheckMate 067 at ClinicalTrials.gov). They observed a survival of 11.4 months for the combined treatment versus 6.9 months for treatment with nivolumab alone and 2.9 months for ipilimumab alone\n[\n39\n](#B39). Although an increase of some months in the survival rate is observed, the immunotherapy has an exorbitant cost: 2015, the average cost per mg of nivolumab was estimated to $28.7, for nivolumab, $51.79 for pembrolizumab and $157.46 for ipilimumab. It should be noted that the administration dosages range from 2 mg/kg to 10 mg/kg every 3 weeks approximately. It is estimated that the cost of a patient's treatment with CheckMate 067 could reach the $295.56; the treatment with nivolumab is estimating in $103,220 and the ipilimumab in $158,252. Taking this into account, for a 75 kg patient with melanoma who wants a treatment with 26 of the highest and most frequent doses of pembrolizumab, the cost would be $ 1,009,944. If this treatment were provided to each of the 589,430 patients who die from melanoma cancer annually, the cost for the health systems would be $ 173,881,850,000. This is simply unsustainable. As in many other areas of the pharmacoeconomics of emerging drugs for chronic diseases, this represents a challenge that must be resolved by considering a balance between the demands of the community and the health systems versus the commercial interests of the entrepreneurs of the pharmaceutical industries [\n40\n](#B40).\n2.8 Adverse effects\nThe use of ipilimumab and tremelimumab has been associated with adverse events affecting the skin (pruritus, vitiligo), intestine (diarrhea and colitis), liver (hepatitis and elevated liver enzymes) and endocrine glands (hypothyroidism, thyroidism)\n[36](#B36). Compared to CTLA-4 blockade, PD-1 or PD-L1 blockade may have similar effects, but they appear to be less common [24](#B24), [36](#B36). Although good results have been shown in the use of these therapies, they are not sufficiently effective to use them alone [35](#B35), which is why their combination with other strategies is necessary. Gene therapy could be an interesting alternative for combined therapy.\n3. Suicide gene therapy\nThe selectivity of the antineoplastic agents is limited because cancer cells are resistant to apoptosis, cell cycle arrest, and senescence. Besides that, some resistant cells subpopulations may emerge in response to the neoplastic agent\n[41](#B41). The application of gene therapy could improve the selectivity of immune-checkpoint directed therapies and facilitate their access to the tumor tissue [42](#B42). Suicide therapy has two alternatives: toxin gene therapy, in which genes for a toxic protein are transduced into tumor cells, or enzyme-activating prodrug therapy. The latter has two steps: initially, a gene of a heterologous enzyme is directed and delivered to the tumor for its expression. Subsequently, a prodrug that can become a cytotoxic drug by the heterologous enzyme is administered [43](#B43). Due to its mechanism of action, this therapy triggers an anti-tumor immunoreactivity, as will be explained below.\nThe herpes simplex virus-thymidine kinase/ganciclovir (HSV-TK/GCV) system is selective for tumor cells because it affects the active replication of DNA, which is one characteristic of tumor cells. This activity is decreased in the surrounding stromal cells, many of which are in the quiescent state\n[42](#B42), [43](#B43).\n3.1 Enzymes and prodrugs used in suicide gene therapy systems\nThe enzymes used in suicide gene therapy are divided into two groups. The first one includes enzymes of non-mammalian origin (e.g. HSV-TK). The second comprises enzymes of human origin that are absent or subexpressed in tumor cells\n[\n43\n](#B43). Several enzyme-prodrug systems have been developed for suicide gene therapy, such as the carboxyl esterase (CE)/irinotecan, carboxypeptidase A (CPA)/MTX-a-peptide, carboxypeptidase G2 (CPG2)/CMDA and HSV-TK/GCV. The HSV-TK/GCV system is the most studied and has progressed successfully to advanced phases in clinical trials, which is explained in more detail below [\n42\n](#B42)\n,\n[\n44\n](#B44).\n3.2 HSV-TK/GCV system\nThe HSV-TK/GCV system uses ganciclovir and its analogs as prodrugs. These are analogs of purine nucleosides\n[\n5\n](#B5)\n,\n[\n42\n](#B42). Systemic administration of GCV induces selective apoptosis in cells transduced with the TK gene. HSV-TK is able to phosphorylate the GCV, turning it into monophosphorylated GCV, which is subsequently tri-phosphorylated by cellular kinases. This product blocks the DNA replication, causing its fragmentation and apoptosis [\n45\n](#B45)\n,\n[\n46\n](#B46)\n[Fig. 4](/pmc/articles/PMC5687866/figure/f4/).\nThe HSV-TK/GCV system has been tested in pre-clinical\n[\n47\n](#B47)\n,\n[\n48\n](#B48) and clinical studies against several types of cancer, such as prostate [\n49\n](#B49)\n,\n[\n50\n](#B50), brain [\n51\n](#B51)\n-\n[\n53\n](#B53), ovarian [\n54\n](#B54)\n,\n[\n55\n](#B55), bladder [\n56\n](#B56)\n,\n[\n57\n](#B57), cervix [\n58\n](#B58), pancreatic [\n59\n](#B59)\n,\n[\n60\n](#B60)\nand liver cancer [\n61\n](#B61), among others. Several phase I and II clinical trials have demonstrated the safety and efficacy of this therapy in humans [\n43\n](#B43)\n,\n[\n44\n](#B44). Other studies have shown that HSV-TK gene transduction is safer and more effective with adenoviral replication deficient vectors compared to retroviral vectors [\n51\n](#B51)\n,\n[\n62\n](#B62).\n3.3 Immune response induced by the AdV-TK/GCV system\nIt has been shown that HSV-TK/GCV therapy induces anti-tumor immunity\n[\n63\n](#B63)\n,\n[\n64\n](#B64) and even regression of brain tumors in immunocompetent rats and neuroblastoma in a murine model [\n65\n](#B65)\n,\n[\n66\n](#B66). In the treated tumors, a marked infiltration of inflammatory cells, predominantly CD4+ and CD8+, is observed. This suggests that the HSV-TK/GCV system stimulates the antitumor immune response [\n50\n](#B50)\n,\n[\n60\n](#B60). The overexpression of different costimulatory molecules such B7.1 and B7.2, intracellular adhesion molecules (ICAM) and MHC molecules, and the attraction and activation of APCs are also observed in tumor tissue [\n67\n](#B67)\n,\n[\n68\n](#B68).\nDuring the HSV-TK/GCV tumor treatment, the levels of some cytokines that stimulate APCs and T cells, such as IL-2, IL-12, IFN\u03b3, TNF\u03b1 and GM-CSF, are increased; whereas inhibitory cytokines like IL- 4, IL-6 and IL-10 are not stimulated\n[\n67\n](#B67). The increase in the immune response has been demonstrated by higher levels of circulating active CD8 cells and elevated IL-12 in serum [\n69\n](#B69)\n,\n[\n70\n](#B70), a key mediator of the cellular immune response against viral infections and malignant tumors [\n69\n](#B69)\n,\n[\n71\n](#B71). Interestingly, NK cell levels have been linked to IL-12 levels, because NK cells are one of the targets of this interleukin [\n69\n](#B69)\n,\n[\n72\n](#B72).\nThe viral TK protein also functions as a superantigen, stimulating a highly immunogenic tumor microenvironment\n[\n68\n](#B68). This protein induces the release and presentation of TAA which can be recognized by T lymphocytes and therefore generate an adaptive immune response. This can lead to tumor cell cytolysis and posterior recruitment of APCs [\n68\n](#B68). The activated APCs induce T cells proliferation by the secretion of IL-2 and IL-12 at the tumor site. All these events are desirable to get a powerful anti-tumor effect [\n73\n](#B73)\n,\n[\n74\n](#B74). However, a contradictory observation should be considered. A clinical trial of HSV-TK/GCV as neoadjuvant therapy for pancreatic carcinoma using an adenoviral vector showed increased intratumoral levels of PD-L1 in samples analyzed after surgical resection. This event may decrease the effector T cell response but may be reversed with co-administration of PD-1 / PD-L1 inhibitors [\n60\n](#B60).\nThe viral vector-mediated HSV-TK/GCV therapy has shown effective progression to phase III in some clinical trials when it was used alone or in combination with chemotherapy or radiation for prostate cancer, hepatocellular carcinoma, or glioblastoma multiforme\n[\n67\n](#B67)\n,\n[\n68\n](#B68)\n,\n[\n75\n](#B75).\n3.4 Adverse effects\nDespite the promising results, there are some disadvantages. The replication-deficient adenoviral vectors trigger a strong humoral and cellular immune response that limits its effectiveness to a period of two to three weeks. Regardless these vectors may be useful for therapeutic applications where a very high level of transient expression of the therapeutic gene is desirable, as would occur in cancer gene therapy\n[\n76\n](#B76). On the other hand, the expression of the TK protein is not tumor specific. An interesting option is the use of adenoviruses that prefer their replication in tumor cells using a specific promoter [\n75\n](#B75).\nPhase I and II studies have shown some side effects, such as mild fever, neutropenia, headache, thrombocytopenia, and impaired hepatic enzymes, among others. Fortunately, these events are transient and easy to tolerate\n[\n49\n](#B49)\n,\n[\n51\n](#B51)\n,\n[\n62\n](#B62).\n4. Combined therapy as a new treatment\nThe combined treatment of gene therapy and immunotherapy is an attractive option that recent advances in cancer therapeutics have made possible. The use of a suicide gene therapy system would lead to the sudden and massive presentation of TAA over a sustained period of weeks or months. It is reasonable to think that this therapy can be synergistically enhanced by its combination with a systemically administered immune-checkpoint inhibitor drug such as those described in this review. To explain this idea in a better way, it could be assumed that a tumor treated with HSV-TK/GCV will generate sudden and massive exposure of TAA to the immune system, which in other conditions wouldn't generate an effective immunoreactivity due to the decrease of MCH I and costimulating molecules and by the induction of Treg. This event would trigger the attraction and activation of APC and some TAA could be expected to induce an increase in the number of intratumoral Treg lymphocytes (even before the intervention with gene therapy), leading to an immunosuppressive environment. In order to prevent this immunological phenomenon and to enhance the antitumor response, subsequent administration of an immune-checkpoint inhibitor, for example an anti-PD1 antibody, would affect the activity of intratumoral Treg cells. This would lead to an increase in the proliferation of the effector T cells capable of fighting the tumor and would reinforce an immune memory response that would potentially have a long-term protective effect\n[\n36\n](#B36).\nRecently performed tests with adenoviral vectors that carry the HSV-TK gene and the PD-1 extracellular domain sequence fused to the Fc portion of mouse IgG2a was recently assayed to produce the soluble PD-1 (sPD1-Ig) segment. This segment inhibits activity of the complete ligand competitively, and consequently, inhibits the apoptotic effect of T cells mediated by the immunosuppressive interaction of the whole ligand with its receptor. This vector was administered in a murine model of colon carcinoma and demonstrated a synergy between HSV/TK therapy and competitive blockade of PD-1/PD-L1 binding. There was a significant decrease in tumor volume in the group of mice treated with HSV-TK/sPD1 compared to the control groups, including the group of mice treated with the simple scheme of HSV-TK / GCV\n[\n77\n](#B77).\nIt is possible that in the near future, preclinical and clinical trials will continue to test hypotheses similar to the one proposed in this section and will certainly have very effective clinical results, and above all, with a high level of therapeutic selectivity, which will favor even more the development of the precision medicine in the area of oncology.\nConclusion\nThe increase of the immune response against tumors could be a key strategy to fight against cancer. The TK/GCV system induces the massive presentation of TAA effectively. On the other hand, the expression of the TK super-antigen facilitates antitumor cellular immunity. The use of monoclonal antibodies against the immune-checkpoints, such as CTLA-4 and PD-1, can decrease the tumor immunosuppression. Until now both strategies are found in clinical trials and have shown promising results. It would be expected that the combination of these two types of therapies would be synergistic, more selective and effective and would have a long-term protective effect.\nReferences\n[Google Scholar](https://scholar.google.com/scholar_lookup?title=Cancer+and+the+immune+system:+the+vital+connection&author=OK+Dzivenu&author=TJ+O'Donnell&publication_year=2003&)] [PMC free article](/pmc/articles/PMC4085883/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/22918931)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Ann+Oncol&title=Immuno-oncology+understanding+the+function+and+dysfunction+of+the+immune+system+in+cancer&author=O+Finn&volume=23&issue=Suppl+8&publication_year=2012&pages=viii6-viii9&pmid=22918931&)] [PMC free article](/pmc/articles/PMC4684975/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/26548534)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Mol+Oncol&title=Cancer+immunotherapy+Strategies+for+personalization+and+combinatorial+approaches&author=V+Sathyanarayanan&author=S+Neelapu&volume=9&issue=10&publication_year=2015&pages=2043-2053&pmid=26548534&)] [PMC free article](/pmc/articles/PMC4856023/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/22437870)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Cancer&title=The+blockade+of+immune+checkpoints+in+cancer+immunotherapy&author=DM+Pardoll&volume=12&issue=4&publication_year=2012&pages=252-264&pmid=22437870&)] [PMC free article](/pmc/articles/PMC4452068/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/26056594)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Mol+Cell+Ther&title=Gene+therapy+for+cancer+present+status+and+future+perspective&author=MH+Amer&volume=2&publication_year=2014&pages=27-27&pmid=26056594&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/25818339)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Semin+Cancer+Biol&title=Immune+evasion+in+cancer+Mechanistic+basis+and+therapeutic+strategies&author=DS+Vinay&author=EP+Ryan&author=G+Pawelec&author=WH+Talib&author=J+Stagg&volume=35&issue=Suppl&publication_year=2015&pages=S185-S198&pmid=25818339&)] [PMC free article](/pmc/articles/PMC4492230/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/26069281)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Oncologist&title=The+evolving+role+of+immune+checkpoint+inhibitors+in+cancer+treatment&author=GK+Pennock&author=LQ+Chow&volume=20&issue=7&publication_year=2015&pages=812-822&pmid=26069281&)] [PMC free article](/pmc/articles/PMC4641952/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/26605342)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Immunol+Res&title=Immune+checkpoint+modulation+in+colorectal+cancer+What's+new+and+what+to+expect&author=J+Jacobs&author=E+Smits&author=F+Lardon&author=P+Pauwels&author=V+Deschoolmeester&volume=2015&publication_year=2015&pages=158038-158038&pmid=26605342&)] [PMC free article](/pmc/articles/PMC4388310/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/24531241)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Curr+Opin+Immunol&title=New+insights+into+cancer+immunoediting+and+its+three+component+phases--elimination,+equilibrium+and+escape&author=D+Mittal&author=MM+Gubin&author=RD+Schreiber&author=MJ+Smyth&volume=27&publication_year=2014&pages=16-25&pmid=24531241&)] [PMC free article](/pmc/articles/PMC5220497/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/28116316)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Immunol+Res&title=The+immune+system+in+cancer+pathogenesis+Potential+therapeutic+approaches&author=PH+Pandya&author=ME+Murray&author=KE+Pollok&author=JL+Renbarger&volume=2016&publication_year=2016&pages=4273943-4273943&pmid=28116316&)] [PMC free article](/pmc/articles/PMC2866629/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/20303878)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Cell&title=Immunity,+inflammation,+and+cancer&author=SI+Grivennikov&author=FR+Greten&author=M+Karin&volume=140&issue=6&publication_year=2010&pages=883-899&pmid=20303878&)] [PMC free article](/pmc/articles/PMC4746082/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/26834161)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Oncologist&title=How+cancers+escape+immune+destruction+and+mechanisms+of+action+for+the+new+significantly+active+immune+therapies+Helping+nonimmunologists+decipher+recent+advances&author=JL+Messerschmidt&author=GC+Prendergast&author=GL+Messerschmidt&volume=21&issue=2&publication_year=2016&pages=233-243&pmid=26834161&)] [PMC free article](/pmc/articles/PMC4788788/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/26967289)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Cell&title=The+basis+of+oncoimmunology&author=AK+Palucka&author=LM+Coussens&volume=164&issue=6&publication_year=2016&pages=1233-1247&pmid=26967289&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/16557261)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Immunol&title=Regulatory+T+cells,+tumor+immunity+and+immunotherapy&author=W+Zou&volume=6&issue=4&publication_year=2006&pages=295-207&pmid=16557261&)] [PMC free article](/pmc/articles/PMC4986235/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/27160722)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Int+Immunol&title=Roles+of+regulatory+T+cells+in+cancer+immunity&author=Y+Takeuchi&author=H+Nishikawa&volume=28&issue=8&publication_year=2016&pages=401-409&pmid=27160722&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/24413387)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Curr+Opin+Immunol&title=Regulatory+T+cells+in+cancer+immunotherapy&author=H+Nishikawa&author=S+Sakaguchi&volume=27&publication_year=2014&pages=1-7&pmid=24413387&)] [PMC free article](/pmc/articles/PMC3530093/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/23199321)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin+Exp+Immunol&title=Suppression,+subversion+and+escape+The+role+of+regulatory+T+cells+in+cancer+progression&author=K+Oleinika&author=RJ+Nibbs&author=GJ+Graham&author=AR+Fraser&volume=171&issue=1&publication_year=2013&pages=36-45&pmid=23199321&)] [PMC free article](/pmc/articles/PMC3983433/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/24833840)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=World+J+Gastroenterol&title=Colorectal+cancer+and+immunity+What+we+know+and+perspectives&author=S+Pernot&author=M+Terme&author=T+Voron&author=O+Colussi&author=E+Marcheteau&volume=20&issue=14&publication_year=2014&pages=3738-3750&pmid=24833840&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/25519074)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Expert+Opin+Investig+Drugs&title=The+potential+role+of+immunotherapy+to+treat+colorectal+cancer&author=M+Amin&author=AC+Lockhart&volume=24&issue=3&publication_year=2015&pages=329-344&)] [PMC free article](/pmc/articles/PMC2665249/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/18566595)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Immunol&title=How+regulatory+T+cells+work&author=DA+Vignali&author=LW+Collison&author=CJ+Workman&volume=8&issue=7&publication_year=2008&pages=523-532&pmid=18566595&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/24276186)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Gac+Med+Mex&title=Mecanismos+de+supresi\u00f3n+de+las+c\u00e9lulas+T+reguladoras+(Treg)&author=JM+Guzm\u00e1n-Flores&author=DP+Portales-P\u00e9rez&volume=149&publication_year=2013&pages=630-638&pmid=24276186&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/17762882)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Cell+Death+Differ&title=Involvement+of+cellular+death+in+TRAIL/DR5-dependent+suppression+induced+by+CD4+CD25++regulatory+T+cells&author=X+Ren&author=F+Ye&author=Z+Jiang&author=Y+Chu&author=S+Xiong&volume=14&publication_year=2007&pages=2076-2084&pmid=17762882&)] [PMC free article](/pmc/articles/PMC4980573/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/25605845)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&title=Immune+checkpoint+blockade+in+cancer+therapy&author=MA+Postow&author=MK+Callahan&author=JD+Wolchok&volume=33&issue=17&publication_year=2015&pages=1974-1982&pmid=25605845&)] [PMC free article](/pmc/articles/PMC5381059/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/28376884)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Biomed+Sci&title=Cancer+immunotherapies+targeting+the+PD-1+signaling+pathway&author=Y+Iwai&author=J+Hamanishi&author=K+Chamoto&author=T+Honjo&volume=24&issue=1&publication_year=2017&pages=26-26&pmid=28376884&)] [PMC free article](/pmc/articles/PMC4289356/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/25606596)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Arthritis+Res+Ther&title=Immune+checkpoint+receptors+in+regulating+immune+reactivity+in+rheumatic+disease&author=S+Ceeraz&author=EC+Nowak&author=CM+Burns&author=RJ+Noelle&volume=16&publication_year=2014&pages=469-469&pmid=25606596&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/28393361)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Eur+J+Immunol&title=Immune+checkpoints+and+their+inhibition+in+cancer+and+infectious+diseases&author=L+Dyck&author=KHG+Mills&volume=47&issue=5&publication_year=2017&pages=765-779&pmid=28393361&)] [PMC free article](/pmc/articles/PMC4717548/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/26788324)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Immunother+Cancer&title=Novel+technologies+and+emerging+biomarkers+for+personalized+cancer+immunotherapy&author=J+Yuan&author=PS+Hegde&author=R+Clynes&author=PG+Foukas&author=A+Harari&volume=4&publication_year=2016&pages=3-3&pmid=26788324&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/19001145)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Oncologist&title=The+mechanism+of+anti-CTLA-4+activity+and+the+negative+regulation+of+T-cell+activation&author=JD+Wolchok&author=Y+Saenger&volume=13&issue=Suppl+l4&publication_year=2008&pages=2-9&pmid=19001145&)] [PMC free article](/pmc/articles/PMC3968368/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/24594636)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Toxins&title=Immune+checkpoint+blockade+in+cancer+treatment:+A+double-edged+sword+cross-targeting+the+host+as+an+\"Innocent+bystander\"&author=L+Gelao&author=C+Criscitiello&author=A+Esposito&author=A+Goldhirsch&author=G+Curigliano&volume=6&issue=3&publication_year=2014&pages=914-933&pmid=24594636&)] [PMC free article](/pmc/articles/PMC3559193/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/23390376)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Cancer+Immun&title=CTLA-4+blockade+in+tumor+models+an+overview+of+preclinical+and+translational+research&author=JF+Grosso&author=MN+Jure-Kunkel&volume=13&publication_year=2013&pages=5-5&pmid=23390376&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/11905831)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Immunol&title=T-cell+regulation+by+CD28+and+CTLA-4&author=ML+Alegre&author=KA+Frauwirth&author=CB+Thompson&volume=1&issue=3&publication_year=2001&pages=220-228&pmid=11905831&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/26091825)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Trends+Mol+Med&title=Checkpoint+blockade+for+cancer+therapy+revitalizing+a+suppressed+immune+system&author=Y+Pico+de+Coa\u00f1a&author=A+Choudhury&author=R+Kiessling&volume=21&issue=8&publication_year=2015&pages=482-491&pmid=26091825&)] [PMC free article](/pmc/articles/PMC4400238/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/25858804)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Cancer+Cell&title=Immune+checkpoint+blockade+A+common+denominator+approach+to+cancer+therapy&author=SL+Topalian&author=CG+Drake&author=DM+Pardoll&volume=27&issue=4&publication_year=2015&pages=450-461&pmid=25858804&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/24089443)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&title=CTLA-4+and+PD-1/PDL1+blockade+new+immunotherapeutic+modalities+with+durable+clinical+benefit+in+melanoma+patients&author=PA+Ott&author=FS+Hodi&author=C+Robert&volume=19&issue=19&publication_year=2013&pages=524-535&pmid=23231950&)] [PMC free article](/pmc/articles/PMC4892769/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/26558876)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Am+J+Clin+Oncol&title=CTLA-4+and+PD-1+pathways+Similarities,+differences,+and+implications+of+their+inhibition&author=EI+Buchbinder&author=A+Desai&volume=39&issue=1&publication_year=2016&pages=98-106&pmid=26558876&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/27192570)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Immunity&title=Targeting+T+cell+co-receptors+for+cancer+therapy&author=MK+Callahan&author=MA+Postow&author=JD+Wolchok&volume=44&issue=5&publication_year=2016&pages=1069-1078&pmid=27192570&)] [PMC free article](/pmc/articles/PMC5795709/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/25713437)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&title=Five-year+survival+rates+for+treatment-naive+patients+with+advanced+melanoma+who+received+ipilimumab+plus+dacarbazine+in+a+phase+III+trial&author=M+Maio&author=JJ+Grob&author=S+Aamdal&author=I+Bondarenko&author=C+Robert&volume=33&issue=10&publication_year=2015&pages=1191-1196&pmid=25713437&)] [PMC free article](/pmc/articles/PMC4901122/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/26899259)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Int+J+Clin+Oncol&title=PD-1/PD-L1+blockade+in+cancer+treatment+perspectives+and+issues&author=J+Hamanishi&author=M+Mandai&author=N+Matsumura&author=K+Abiko&author=T+Baba&volume=21&publication_year=2016&pages=462-473&pmid=26899259&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/26398076)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&title=Combined+nivolumab+and+ipilimumab+or+monotherapy+in+untreated+Melanoma&author=J+Larkin&author=FS+Hodi&author=JD+Wolchok&volume=373&issue=13&publication_year=2015&pages=1270-1271&)] [PMC free article](/pmc/articles/PMC4570079/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/26380599)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Am+Health+Drug+Benefits&title=Treating+with+checkpoint+inhibitor+Figure+$1+million+per+patient&author=A+Andrews&volume=8&publication_year=2015&pages=9-9&pmid=26380599&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/15077157)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Oncogene&title=Prospective+strategies+to+enforce+selectively+cell+death+in+cancer+cells&author=MV+Blagosklonny&volume=23&issue=16&publication_year=2004&pages=2967-2975&pmid=15077157&)] [PMC free article](/pmc/articles/PMC4758904/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/26004498)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Adv+Drug+Deliv+Rev&title=Progress+and+problems+with+the+use+of+suicide+genes+for+targeted+cancer+therapy&author=Z+Karjoo&author=X+Chen&author=A+Hatefi&volume=99&issue=A&publication_year=2016&pages=113-128&pmid=26004498&)] [PMC free article](/pmc/articles/PMC5423469/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/28548065)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Biomedicines&title=Gene+therapy+used+in+cancer+treatment&author=T+Wirth&author=S+Yla-Herttuala&volume=2&issue=2&publication_year=2014&pages=149-162&pmid=28548065&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/15001663)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Pharmacol+Rev&title=Enzyme-catalyzed+activation+of+anticancer+prodrugs&author=M+Rooseboom&author=JN+Commandeur&author=NP+Vermeulen&volume=56&issue=1&publication_year=2004&pages=53-02&pmid=15001663&)] [PMC free article](/pmc/articles/PMC184786/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/6307132)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Antimicrob+Agents+Chemother&title=Anti-herpesvirus+activity+of+the+acyclic+nucleoside+9-(1,3-dihydroxy-2-propoxymethyl)guanine&author=DF+Smee&author=JC+Martin&author=JP+Verheyden&author=TR+Matthews&volume=23&issue=5&publication_year=1983&pages=676-682&pmid=6307132&)] [PMC free article](/pmc/articles/PMC5415956/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/28624190)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Mol+Ther+Nucleic+Acids&title=Expression+of+Herpes+Simplex+Virus+thymidine+kinase/ganciclovir+by+RNA+trans-splicing+induces+selective+killing+of+HIV-producing+cells&author=CK+Ingemarsdotter&author=C+Poddar&author=C+Mercier&author=V+Patzel&author=AM+Lever&volume=7&publication_year=2017&pages=140-154&pmid=28624190&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/9917091)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Cancer+Gene+Ther&title=Distribution,+persistency,+toxicity,+and+lack+of+replication+of+an+E1A-deficient+adenoviral+vector+after+intracardiac+delivery+in+the+cotton+rat&author=A+Rojas-Martinez&author=PR+Wyde&author=CA+Montgomery&author=SH+Chen&author=SL+Woo&volume=5&issue=6&publication_year=1998&pages=365-370&pmid=9917091&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/22634584)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Cancer+Lett&title=Suicide+gene+therapy+in+cancer+where+do+we+stand+now?&author=S+Duarte&author=G+Carle&author=H+Faneca&author=MC+de+Lima&author=V+Pierrefite-Carle&volume=324&issue=2&publication_year=2012&pages=160-170&pmid=22634584&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/10340555)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Hum+Gene+Ther&title=In+situ+gene+therapy+for+adenocarcinoma+of+the+prostate+a+phase+I+clinical+trial&author=JR+Herman&author=HL+Adler&author=E+Aguilar-Cordova&author=A+Rojas-Martinez&author=S+Woo&volume=10&issue=7&publication_year=1999&pages=1239-1249&pmid=10340555&)] [PMC free article](/pmc/articles/PMC3842423/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/24052127)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Cancer+Gene+Ther&title=Intraprostatic+distribution+and+long+term+follow-up+after+AdV-tk+++prodrug+as+neoadjuvant+to+surgery+in+patients+with+prostate+cancer&author=A+Rojas-Mart\u00ednez&author=AG+Manzanera&author=SW+Sukin&author=J+Esteban-Mar\u00eda&author=JF+Gonz\u00e1lez-Guerrero&volume=20&issue=11&publication_year=2013&pages=642-649&pmid=24052127&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/10933931)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Mol+Ther&title=Phase+I+study+of+adenoviral+delivery+of+the+HSV-tk+gene+and+ganciclovir+administration+in+patients+with+recurrent+malignant+brain+tumors&author=TW+Trask&author=RP+Trask&author=E+Aguilar-C\u00f3rdova&author=HD+Shine&author=PR+Wyde&volume=1&issue=2&publication_year=2000&pages=195-103&pmid=10933931&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/24756350)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Neurooncol&title=Prognostic+utility+of+gene+therapy+with+herpes+simplex+virus+thymidine+kinase+for+patients+with+high-grade+malignant+gliomas+a+systematic+review+and+meta-analysis&author=F+Zhao&author=J+Tian&author=L+An&author=K+Yang&volume=118&issue=2&publication_year=2014&pages=239-246&pmid=24756350&)] [PMC free article](/pmc/articles/PMC4467037/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/26067671)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=PLoS+One&title=The+anti-tumor+effects+of+adipose+tissue+mesenchymal+stem+cell+transduced+with+HSV-TK+gene+on+U-87-driven+brain+tumor&author=SM+de+Melo&author=S+Bittencourt&author=EG+Ferrazoli&author=CS+da+Silva&author=FF+da+Cunha&volume=10&issue=6&publication_year=2015&pages=e0128922&pmid=26067671&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/11860538)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Int+J+Gynecol+Cancer&title=Histologic+and+immunohistochemical+analysis+of+tissue+response+to+adenovirus-mediated+herpes+simplex+thymidine+kinase+gene+therapy+of+ovarian+cancer&author=A+Hasenburg&author=DC+Fischer&author=XW+Tong&author=A+Rojas-Mart\u00ednez&author=C+Nyberg-Hoffman&volume=12&issue=1&publication_year=2002&pages=66-73&pmid=11860538&)] [PMC free article](/pmc/articles/PMC4440683/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/26005395)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Gene+Ther+Mol+Biol&title=Adenoviral-delivered+HE4-HSV-tk+sensitizes+ovarian+cancer+cells+to+ganciclovir&author=JW+Rawlinson&author=K+Vaden&author=J+Hunsaker&author=DF+Miller&author=KP+Nephew&volume=15&publication_year=2013&pages=120-130&pmid=26005395&)] [PMC free article](/pmc/articles/PMC2803447/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/20015348)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Exp+Clin+Cancer+Res&title=A+novel+Bifidobacterium+infantis-mediated+TK/GCV+suicide+gene+therapy+system+exhibits+antitumor+activity+in+a+rat+model+of+bladder+cancer&author=W+Tang&author=Y+He&author=S+Zhou&author=Y+Ma&author=G+Liu&volume=28&issue=1&publication_year=2009&pages=155-155&pmid=20015348&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/24273940)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin+Lab&title=Potent+antitumor+activity+of+the+combination+of+HSV-TK+and+endostatin+by+adeno-associated+virus+vector+for+bladder+cancer+in+vivo&author=JG+Pan&author=RQ+Luo&author=X+Zhou&author=RF+Han&author=GW+Zeng&volume=59&issue=9-10&publication_year=2013&pages=1147-1158&pmid=24273940&)] [PMC free article](/pmc/articles/PMC2988757/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/21054886)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=BMC+Cancer&title=An+experimental+study+on+cervix+cancer+with+combination+of+HSV-TK/GCV+suicide+gene+therapy+system+and+Co+radiotherapy&author=D+Chen&author=Q+Tang&volume=10&publication_year=2010&pages=609-620&pmid=21054886&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/20599444)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Biochim+Biophys+Acta&title=Cell+cycle+control+pathways+act+as+conditioning+factors+for+TK/GCV+sensitivity+in+pancreatic+cancer+cells&author=DD+Abate&author=LR+Garc\u00eda&author=L+Sumoy&author=C+Fillat&volume=1803&issue=10&publication_year=2010&pages=1175-1185&pmid=20599444&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/25795132)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Cancer+Immunol+Immunother&title=Gene-mediated+cytotoxic+immunotherapy+as+adjuvant+to+surgery+or+chemoradiation+for+pancreatic+adenocarcinoma&author=LK+Aguilar&author=LA+Shirley&author=VM+Chung&author=CL+Marsh&author=J+Walker&volume=64&issue=6&publication_year=2015&pages=727-736&pmid=25795132&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/25073402)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Pharmazie&title=Adenovirus+vector-mediated+herpes+simplex+virus-thymidine+kinase+gene/ganciclovir+system+exhibits+anti-tumor+effects+in+an+orthotopic+hepatocellular+carcinoma+model&author=R+Zhu&author=D+Chen&author=D+Lin&author=F+Lu&author=J+Yin&volume=69&issue=7&publication_year=2014&pages=547-552&pmid=25073402&)] [PMC free article](/pmc/articles/PMC4826211/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/26716896)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Oncotarget&title=Adenovirus-mediated+delivery+of+herpes+simplex+virus+thymidine+kinase+administration+improves+outcome+of+recurrent+high-grade+glioma&author=N+Ji&author=D+Weng&author=C+Liu&author=Z+Gu&author=S+Chen&volume=7&issue=4&publication_year=2016&pages=4369-4378&pmid=26716896&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/10854148)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=World+J+Urol&title=Prospects+for+herpes-simplex-virus+thymidine-kinase+and+cytokine+gene+transduction+as+immunomodulatory+gene+therapy+for+prostate+cancer&author=W+Hassan&author=MA+Sanford&author=SL+Woo&author=SH+Chen&author=SJ+Hall&volume=18&issue=2&publication_year=2000&pages=130-135&pmid=10854148&)] [PMC free article](/pmc/articles/PMC4471533/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/26137259)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Mol+Clin+Oncol&title=Enhanced+central+memory+cluster+of+differentiation+8++and+tumor+antigen-specific+T+cells+in+prostate+cancer+patients+receiving+repeated+in+situ+adenovirus-mediated+suicide+gene+therapy&author=M+Kubo&author=T+Satoh&author=KI+Tabata&author=H+Tsumura&author=M+Iwamura&volume=3&issue=3&publication_year=2015&pages=515-521&pmid=26137259&)] [PMC free article](/pmc/articles/PMC43782/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/8183911)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+U+S+A&title=Development+of+anti-tumor+immunity+following+thymidine+kinase-mediated+killing+of+experimental+brain+tumors&author=D+Barba&author=J+Hardin&author=M+Sadelain&author=FH+Gage&volume=91&issue=10&publication_year=1994&pages=348-352&)] [PMC free article](/pmc/articles/PMC2822245/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/14966351)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Korean+Med+Sci&title=Bystander-mediated+regression+of+murine+neuroblastoma+via+retroviral+transfer+of+the+HSV-TK+gene&author=HS+Cho&author=HR+Lee&author=MK+Kim&volume=19&issue=1&publication_year=2004&pages=107-112&pmid=14966351&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/21465529)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Cell+Biochem&title=Cytotoxic+immunotherapy+strategies+for+cancer+mechanisms+and+clinical+development&author=LK+Aguilar&author=BW+Guzik&author=E+Aguilar-Cordova&volume=112&publication_year=2011&pages=1969-1977&pmid=21465529&)] [PMC free article](/pmc/articles/PMC4933478/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/26843484)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Neuro+Oncol&title=Phase+II+multicenter+study+of+gene-mediated+cytotoxic+immunotherapy+as+adjuvant+to+surgical+resection+for+newly+diagnosed+malignant+glioma&author=LA+Wheeler&author=AG+Manzanera&author=SD+Bell&author=R+Cavaliere&author=JM+McGregor&volume=18&issue=8&publication_year=2016&pages=1137-1145&pmid=26843484&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/16480930)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Mol+Ther&title=Biological+response+determinants+in+HSV-tk+++ganciclovir+gene+therapy+for+prostate+cancer&author=G+Ayala&author=T+Satoh&author=R+Li&author=M+Shalev&author=Y+Gdor&volume=13&issue=4&publication_year=2006&pages=716-728&pmid=16480930&)] [PMC free article](/pmc/articles/PMC3129286/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/21738557)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Future+Virol&title=Implications+of+the+innate+immune+response+to+adenovirus+and+adenoviral+vectors&author=SM+Gregory&author=SA+Nazir&author=JP+Metcalf&volume=6&issue=3&publication_year=2011&pages=357-374&pmid=21738557&)] [PMC free article](/pmc/articles/PMC4151806/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/25051201)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Int+J+Oncol&title=A+novel+cancer+vaccine+strategy+with+combined+IL-18+and+HSV-TK+gene+therapy+driven+by+the+hTERT+promoter+in+a+murine+colorectal+cancer+model&author=K+Higashi&author=S+Hazama&author=A+Araki&author=K+Yoshimura&author=N+Iizuka&volume=45&issue=4&publication_year=2014&pages=1412-1420&pmid=25051201&)] [PMC free article](/pmc/articles/PMC5384344/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/28405496)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Oncoimmunology&title=IL-12,+IL-15,+and+IL-18+pre-activated+NK+cells+target+resistant+T+cell+acute+lymphoblastic+leukemia+and+delay+leukemia+development+in+vivo&author=M+Boieri&author=A+Ulvmoen&author=A+Sudworth&author=C+Lendrem&author=M+Collin&volume=6&issue=3&publication_year=2017&pages=e1274478&pmid=28405496&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/9139853)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Int+J+Cancer&title=Generation+of+an+anti-tumour+immune+response+in+a+non-immunogenic+tumour+HSVtk+killing+in+vivo+stimulates+a+mononuclear+cell+infiltrate+and+a+Th1-like+profile+of+intratumoural+cytokine+expression&author=RG+Vile&author=S+Castleden&author=J+Marshall&author=R+Camplejohn&author=C+Upton&volume=71&issue=2&publication_year=1997&pages=267-274&pmid=9139853&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/15638715)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Curr+Gene+Ther&title=In+situ+gene+therapy+for+prostate+cancer&author=T+Satoh&author=A+Irie&author=S+Egawa&author=S+Baba&volume=5&issue=1&publication_year=2005&pages=111-119&pmid=15638715&)] [PMC free article](/pmc/articles/PMC3983249/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/24722669)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=PLoS+One&title=A+systematic+comparison+of+the+anti-tumoural+activity+and+toxicity+of+the+three+Adv-TKs&author=Q+Gao&author=C+Chen&author=T+Ji&author=P+Wu&author=Z+Han&volume=9&issue=4&publication_year=2014&pages=e94050&pmid=24722669&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/12728277)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Genet&title=Progress+and+problems+with+the+use+of+viral+vectors+for+gene+therapy&author=CE+Thomas&author=A+Ehrhardt&author=MA+Kay&volume=4&publication_year=2003&pages=346-358&pmid=12728277&)] [PMC free article](/pmc/articles/PMC3589170/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/23337984)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Mol+Ther&title=Adenovirus+expressing+both+thymidine+kinase+and+soluble+PD1+enhances+antitumor+immunity+by+strengthening+CD8+T-cell+response&author=SP+Shin&author=HH+Seo&author=JH+Shin&author=HB+Park&author=DP+Lim&volume=21&issue=3&publication_year=2013&pages=688-695&pmid=23337984&)] [PMC free article](/pmc/articles/PMC3786574/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/23470321)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Immunol&title=Molecular+mechanisms+of+T+cell+co-stimulation+and+co-inhibition&author=L+Chen&author=DB+Flies&volume=13&issue=4&publication_year=2013&pages=227-242&pmid=23470321&)] [PMC free article](/pmc/articles/PMC4005613/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/23868869)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&title=Molecular+pathways+co-expression+of+immune+checkpoint+molecules:+signaling+pathways+and+implications+for+cancer+immunotherapy&author=CJ+Nirschl&author=CG+Drake&volume=19&issue=18&publication_year=2013&pages=4917-4924&pmid=23868869&)] [http://clinicaltrials.gov](http://clinicaltrials.gov). [10.25100/cm.v48i3.2997](//doi.org/10.25100%2Fcm.v48i3.2997)\nInmunoterapia y terapia g\u00e9nica como nuevos tratamientos contra el c\u00e1ncer\nIntroducci\u00f3n\nLa progresi\u00f3n de muchos tipos de c\u00e1ncer se acompa\u00f1a de una fuerte supresi\u00f3n del sistema inmune (SI), lo que interfiere con la respuesta antitumoral y la erradicaci\u00f3n eficaz del tumor\n[1](#B1). La evasi\u00f3n de la inmuno-vigilancia es atribuida, en parte, a que el microambiente tumoral puede inhibir la proliferaci\u00f3n de linfocitos T y atraer a poblaciones celulares supresoras [2](#B2).\nLa mejor comprensi\u00f3n del sistema inmunol\u00f3gico del tumor ha permitido el desarrollo de terapias espec\u00edficas dise\u00f1adas para mejorar la respuesta inmune de un paciente. La inmunoterapia tumoral tiene dos estrategias: atacar al tumor directamente o activar el SI usando terapias celulares, como la estimulaci\u00f3n con agonistas o el bloqueo de puntos de control inmunol\u00f3gicos\n[3](#B3). Este \u00faltimo libera el potencial de la respuesta inmune antitumoral, mostrando ser una terapia prometedora [4](#B4). Otra opci\u00f3n antitumoral es el uso de modalidades de terapia g\u00e9nica, que permiten modificar la expresi\u00f3n g\u00e9nica con prop\u00f3sitos terap\u00e9uticos. Por ejemplo, \u00e9sta puede facilitar la transducci\u00f3n de c\u00e9lulas tumorales con \"genes suicidas\", una de las estrategias de terapia g\u00e9nica antitumoral m\u00e1s investigadas [5](#B5).\nEn este art\u00edculo se hace una revisi\u00f3n del uso de terapia g\u00e9nica suicida y el bloqueo de los puntos de control inmunol\u00f3gicos como alternativas para el tratamiento del c\u00e1ncer y se analizan los posibles efectos sin\u00e9rgicos que podr\u00edan lograrse con la combinaci\u00f3n de estas dos terapias.\n1. C\u00e1ncer y el sistema inmune\nEl SI interact\u00faa \u00edntimamente con los tumores durante el proceso del desarrollo de la enfermedad y su progresi\u00f3n a met\u00e1stasis (inmunolog\u00eda tumoral)\n[6](#B6). El SI responde al c\u00e1ncer, reconociendo y eliminando las c\u00e9lulas anormales (inmuno-vigilancia) [7](#B7). Sin embargo, algunas c\u00e9lulas resistentes escapan de este control (inmunoedici\u00f3n) [8](#B8) disminuyendo su inmunogenicidad [9](#B9), promoviendo el crecimiento maligno [7](#B7).\nLas c\u00e9lulas tumorales presentan cambios en sus marcadores de superficie. Por ejemplo, expresan ant\u00edgenos asociados a tumor (TAA)\n[10](#B10) o disminuyen la expresi\u00f3n del complejo mayor de histocompatibilidad (MHC) de clase I. Esto puede activar c\u00e9lulas de la respuesta inmune innata, como las c\u00e9lulas asesinas naturales (NK) [10](#B10). Los macr\u00f3fagos y neutr\u00f3filos atacan las c\u00e9lulas tumorales y estimulan a los linfocitos T citot\u00f3xicos (CTL), a las c\u00e9lulas presentadoras de ant\u00edgeno (APC) y a las NK. En contraste, las c\u00e9lulas inflamatorias producen factores de crecimiento tumorales (TGF) y factores estimuladores de la angiog\u00e9nesis que contribuyen al desarrollo del tumor [11](#B11).\nEn la respuesta adaptativa, los TAA procesados son presentados por mol\u00e9culas MHC clase I y II de las APC a los receptores espec\u00edficos para la activaci\u00f3n de las c\u00e9lulas T CD8+ o CD4+, respectivamente\n[10](#B10), [12](#B12). Los linfocitos T CD8+ son consideradas las principales c\u00e9lulas efectoras antitumorales [13](#B13). Una vez que son activadas, median la lisis de las c\u00e9lulas cancerosas [10](#B10). Dentro de las c\u00e9lulas T CD4+, las Th1 son responsables de la inmunidad celular: secretan interleucina (IL)-2, TNF\u03b1 e interfer\u00f3n-\u03b3 (IFN-\u03b3), promueven la actividad citot\u00f3xica de los macr\u00f3fagos e inducen la sobreexpresi\u00f3n de MHC I y II en las APC. En contraste, las c\u00e9lulas Th2 expresan IL-4,- 5, -10 y -13, induciendo anergia clonal, potenciando la inmunidad humoral y regulando la actividad de los macr\u00f3fagos [13](#B13). Por otro lado, los linfocitos T reguladores (Treg), ayudan a reducir la inflamaci\u00f3n produciendo TGF-\u03b2, IL-35 e IL-10 [10](#B10). Las c\u00e9lulas tumorales pueden secretar quimiocinas como CCL22 para reclutar c\u00e9lulas Treg con el objetivo de suprimir la funci\u00f3n efectora de las c\u00e9lulas T y disminuir la respuesta inmune [10](#B10).\nLos tumores tambi\u00e9n pueden desregular el SI alterando un complejo balance entre se\u00f1ales inhibitorias (puntos de control) y activadoras en diferentes v\u00edas que regulan la acci\u00f3n de las c\u00e9lulas T\n[7](#B7).\n2. Linfocitos T reguladores\nLos linfocitos Treg son relevantes para el mantenimiento de la homeostasis inmunol\u00f3gica: mantienen la tolerancia a ant\u00edgenos propios, evitan la aparici\u00f3n de enfermedades autoinmunes, controlan el desarrollo de una respuesta inmune y favorecen el escape de las c\u00e9lulas tumorales del control inmunol\u00f3gico\n[14](#B14),\n[15](#B15)\n. La subpoblaci\u00f3n mejor caracterizada expresa CD4, CD25 y Foxp3. Las poblaciones celulares que son suprimidas por los linfocitos Treg incluyen a los linfocitos T CD4+ y CD8+, las c\u00e9lulas T naturales asesinas T (c\u00e9lulas NKT), las c\u00e9lulas dendr\u00edticas (DCs), los monocitos/macr\u00f3fagos, los linfocitos B y las c\u00e9lulas NK [14](#B14).\nDebido a que los Treg suprimen la respuesta inmune contra ant\u00edgenos propios\n[8](#B8), [16](#B16), se postula que los TAAs pueden inducir un incremento en el n\u00famero de linfocitos Treg intratumorales en varias neoplasias, incluyendo el c\u00e1ncer colorrectal (CRC), facilitando la inmunotolerancia tumoral [8](#B8), [17](#B17). La acumulaci\u00f3n de Treg en tumores se explica por varios mecanismos, como la conversi\u00f3n de c\u00e9lulas T CD4+ a Treg en respuesta a TGF-\u03b2 de membrana, el reclutamiento de Tregs por las quimiocinas CCL17, CCL22 y CCL28 o la secreci\u00f3n tumoral de VEGF-A en respuesta a la hipoxia, lo cual inhibe la maduraci\u00f3n de DC. Las DC inmaduras expresan TGF-\u03b2 favoreciendo la conversi\u00f3n de c\u00e9lulas T CD4+ a Treg [18](#B18).\nLos TAA m\u00e1s frecuentes son ant\u00edgenos propios poco expresados en c\u00e9lulas normales, pero altamente expresados en las tumorales\n[18](#B18). El ant\u00edgeno carcinoembrionario (CEA) expresado altamente en CRC [18](#B18), uno de los mejor conocidos, es reconocido como ant\u00edgeno propio por los Tregs [19](#B19), ocasionando una respuesta inmune deficiente frente a las c\u00e9lulas tumorales. En c\u00e1nceres de ovario, mama, p\u00e1ncreas, est\u00f3mago e h\u00edgado, un incremento de linfocitos Treg en el tumor se asocia a empeoramiento del pron\u00f3stico17. El uso de estas c\u00e9lulas como blanco puede impactar las estrategias terap\u00e9uticas contra el c\u00e1ncer [8](#B8).\n2.1 Mecanismos de acci\u00f3n de los linfocitos Treg\nLos linfocitos Treg tienen cuatro mecanismos principales de acci\u00f3n para regular la respuesta inmune\n[Fig. 1](/pmc/articles/PMC5687866/figure/f5/). El primero es la supresi\u00f3n por citocinas inhibitorias, las cuales incluyen IL-3, IL-10 y TGF\u03b2 [18](#B18), [20](#B20). El segundo es la supresi\u00f3n por cit\u00f3lisis. Los Treg pueden tener inducir cit\u00f3lisis de las c\u00e9lulas B por medio de la producci\u00f3n de granzima B. Estas c\u00e9lulas tambi\u00e9n pueden ejercer un efecto citol\u00edtico en linfocitos T CD8+ y c\u00e9lulas NK mediado por granzima B y perforina, o por la v\u00eda aTRAIL-DR5 [20](#B20)- [22](#B22). El tercero es la supresi\u00f3n por alteraciones metab\u00f3licas que afectan la actividad de mol\u00e9culas como CD25 (receptor de IL-2), AMP c\u00edclico (cAMP), CD39, CD73 y el receptor de adenosina 2A (A2AR) [20](#B20). El cuarto mecanismo consiste en la supresi\u00f3n de la maduraci\u00f3n o de la funci\u00f3n de DC. Esto incluye v\u00edas como la del gen 3 de activaci\u00f3n de linfocitos (LAG3) o la interacci\u00f3n entre el ant\u00edgeno asociado a los linfocitos T citot\u00f3xicos (CTLA-4) y CD80/86, la cual induce a la enzima indoleamina-2,3-dioxigenasa (IDO), una mol\u00e9cula inmunosupresora generada por las DC [10](#B10), [20](#B20). El bloqueo de estos mecanismos inmunosupresores podr\u00eda incrementar la funci\u00f3n de las c\u00e9lulas T y generar una respuesta cl\u00ednica m\u00e1s efectiva [8](#B8), [20](#B20).\n2.2 Regulaci\u00f3n de los puntos de control inmunol\u00f3gicos por medio de linfocitos Treg\nEn el caso de las c\u00e9lulas T, la amplitud y calidad de la respuesta despu\u00e9s del reconocimiento de un ant\u00edgeno, est\u00e1 regulada por un balance entre se\u00f1ales coestimuladoras e inhibitorias (puntos de control inmunol\u00f3gico)\n[4](#B4). Con el objetivo de aumentar la funci\u00f3n efectora de las c\u00e9lulas T infiltrantes de tumor, se pueden inhibir las se\u00f1ales inmunosupresoras; de esta manera, se ha tenido un mayor \u00e9xito cl\u00ednico en el tratamiento de varios tipos de c\u00e1ncer, como melanoma y c\u00e1ncer de pulm\u00f3n [6](#B6). Las mol\u00e9culas que act\u00faan como puntos de control inmunol\u00f3gico, como el receptor CTLA-4 y la prote\u00edna de muerte celular programada 1 (PD-1), son expresadas en los linfocitos Treg y en las c\u00e9lulas T efectoras infiltrantes de tumor [15](#B15).\n2.3 Puntos de control inmunol\u00f3gico en c\u00e1ncer\nComo se coment\u00f3 previamente, la activaci\u00f3n e inhibici\u00f3n de diferentes receptores regula el balance entre la respuesta y la tolerancia inmune\n[23](#B23), [24](#B24), siendo estos importantes para una completa activaci\u00f3n y funci\u00f3n efectora de las c\u00e9lulas T [25](#B25). La terapia con anticuerpos contra reguladores inmunol\u00f3gicos negativos ha demostrado \u00e9xito en el tratamiento antineopl\u00e1sico [23](#B23), [25](#B25), debido a que aumenta el potencial de la respuesta inmune antitumoral. Est\u00e1 demostrado que los tumores usan algunas v\u00edas de control inmunol\u00f3gico como mecanismo de resistencia inmune [4](#B4), ya que al incrementarse la expresi\u00f3n de las prote\u00ednas de los puntos de control, decrece la funci\u00f3n de las c\u00e9lulas T. Ejemplos de puntos de control inmunol\u00f3gicos son PD-1, CTLA-4, LAG-3, inmunoglobulina de c\u00e9lula T (TIM-3), entre otros [26](#B26).\nLos anticuerpos antitumorales que bloquean los puntos de control inmunol\u00f3gico est\u00e1n dirigidos contra receptores de linfocitos o sus ligandos\n[27](#B27)\n[Tabla 1](/pmc/articles/PMC5687866/table/t2/). Dos puntos de control inmunol\u00f3gicos ampliamente estudiados en el contexto cl\u00ednico de la inmunoterapia contra el c\u00e1ncer son CTLA-4 y PD-1; ambos son receptores inhibitorios que regulan la respuesta inmune [27](#B27). Aunque la inhibici\u00f3n de los puntos de control parece ser exitosa en el tratamiento de algunos c\u00e1nceres, est\u00e1 asociada eventos adversos, en particular a respuestas autoinmunes que afectan a \u00f3rganos como el colon, la piel, algunas gl\u00e1ndulas end\u00f3crinas, el h\u00edgado, etc [26](#B26).\nTabla 1\n|Blanco||Funci\u00f3n biol\u00f3gica||Anticuerpo||Situaci\u00f3n en cl\u00ednica|\n|CTLA-4||Receptor inhibitorio||Ipilimumab||Aprobado por la FDA para melanoma. Ensayos de fase IV para melanoma y c\u00e1ncer metast\u00e1sico de c\u00e9lulas renales. Ensayos de fase III para c\u00e1ncer de est\u00f3mago/es\u00f3fago, c\u00e1ncer de pulm\u00f3n de c\u00e9lulas peque\u00f1as y no peque\u00f1as, carcinoma renal, mesotelioma pleural, carcinoma metast\u00e1sico de c\u00e9lulas escamosas de cabeza y cuello, c\u00e1ncer de pr\u00f3stata, melanoma ocular.|\n|Tremelimumab||Probado en ensayos de fase III para melanoma, c\u00e1ncer de cabeza y cuello, c\u00e1ncer de c\u00e9lulas de pulm\u00f3n peque\u00f1as y no peque\u00f1as, c\u00e1ncer urotelial,|\n|PD-1||Receptor inhibitorio||Nivolumab||Aprobado por la FDA para melanoma, carcinoma renal, c\u00e1ncer de c\u00e9lulas de pulm\u00f3n no peque\u00f1as. Ensayos de fase IV para carcinoma renal metast\u00e1sico avanzado y melanoma metast\u00e1sico. Ensayos fase III para c\u00e1ncer de pulm\u00f3n de c\u00e9lulas peque\u00f1as y no peque\u00f1as, c\u00e1ncer de est\u00f3mago/es\u00f3fago, melanoma, mesotelioma, carcinoma hepatocelular, mieloma m\u00faltiple, c\u00e1ncer urotelial, c\u00e1ncer g\u00e1strico|\n|Pembrolizumab||Aprobado por la FDA para melanoma, c\u00e1ncer de c\u00e9lulas de pulm\u00f3n no peque\u00f1as. Ensayos de fase III para melanoma y c\u00e1ncer de pulm\u00f3n de c\u00e9lulas peque\u00f1as y no peque\u00f1as.|\n|Pidilizumab||Ensayos de fase I/II para linfoma, mieloma m\u00faltiple, c\u00e1ncer de p\u00e1ncreas.|\n|PDL1||Ligando de PD-1||BMS-936559||Ensayos de fase I para melanoma.|\n|Atezolizumab||Ensayos de fase III para c\u00e1ncer de pulm\u00f3n de c\u00e9lulas peque\u00f1as y no peque\u00f1as, c\u00e1ncer de mama triple negativo, c\u00e1ncer de tracto urinario, c\u00e1ncer renal, c\u00e1ncer de ovario, c\u00e1ncer colorrectal, melanoma.|\n|LAG3||Receptor inhibitorio||IMP321||Ensayos de fase I/II para adenocarcinoma de mama, carcinoma renal, melanoma, neoplasias pancre\u00e1ticas.|\n|B7-H3||Ligando inhibitorio||Enoblituzumab||Ensayos de fase I para v\u00e1rios tipos de c\u00e1ncer.|\nCTLA-4: ant\u00edgeno asociado a linfocitos T citot\u00f3xicos\nLAG3: gen 3 de activaci\u00f3n a linfocitos\nPD-1: receptor prote\u00edco de muerte celular programada 1\nPDL1: ligando de PD-1\n2.4 CTLA-4\nEl receptor CTLA-4 es el primer punto de control inmunol\u00f3gico usado como blanco cl\u00ednico\n[28](#B28). CTLA-4 es miembro de la s\u00faper-familia de las inmunoglobulinas CD28:B7, normalmente es expresado en bajos niveles en la superficie de las c\u00e9lulas T efectoras y c\u00e9lulas Treg. Su funci\u00f3n es regular la amplitud de las primeras etapas de la activaci\u00f3n de estas c\u00e9lulas [28](#B28). Para que una c\u00e9lula T se active se requieren tres se\u00f1ales: la uni\u00f3n del ant\u00edgeno con el receptor de c\u00e9lulas T (TCR), la interacci\u00f3n del MHC (en humanos ant\u00edgeno leucocitario humano, HLA) con los receptores CD8 o CD4 de las c\u00e9lulas T y la generaci\u00f3n de una se\u00f1al coestimuladora generada por la uni\u00f3n de CD80(B7) con CD28 [12](#B12), [29](#B29). Una vez que esto ocurre, la v\u00eda de CD28 amplifica la se\u00f1alizaci\u00f3n del TCR para activar la proliferaci\u00f3n de las c\u00e9lulas T. CD28 y CTLA-4 comparten los mismos ligandos: CD80(B7.1) y CD86(B7.2), aunque estos se unen a CTLA-4 con mayor afinidad [4](#B4), [30](#B30), debido a esto, CTLA-4 contrarresta la actividad coestimuladora de CD28 [4](#B4), [31](#B31).\nLa importancia de CTLA-4 en la activaci\u00f3n de c\u00e9lulas T est\u00e1 demostrada por el fenotipo letal del sistema inmune hiperactivado en ratones knockout para CTLA-44. A pesar de que CTLA-4 se expresa en c\u00e9lulas efectoras T CD8+ activadas, su funci\u00f3n fisiol\u00f3gica m\u00e1s importante se ejerce a trav\u00e9s de distintos efectos en los dos subconjuntos principales de c\u00e9lulas T CD4+: la disminuci\u00f3n de la actividad de las c\u00e9lulas T cooperadoras (Th1) y el potenciamiento de la actividad inmunosupresora de las c\u00e9lulas Treg\n[4](#B4).\nSe ha propuesto que la expresi\u00f3n de CTLA-4 aten\u00faa la activaci\u00f3n de las c\u00e9lulas T por una cascada de se\u00f1ales inhibitorias\n[Fig. 2](/pmc/articles/PMC5687866/figure/f6/), as\u00ed como por su competencia con CD28 [30](#B30). Algunos estudios sugieren que la activaci\u00f3n de las prote\u00edna tirosina fosfatasa (SHP2) y de la prote\u00edna fosfatasa 2A (PP2A) contrarrestan las se\u00f1ales de las quinasas inducidas por TCR y CD28 [30](#B30). Otros mecanismos, incluyen la expansi\u00f3n de c\u00e9lulas Treg, estas producen citocinas inmunosupresoras como TGF-\u03b2 y la enzima IDO [32](#B32).\nEl bloqueo de CTLA-4 puede afectar la respuesta inmune intratumoral mediante la inactivaci\u00f3n de los linfocitos Treg infiltrantes de tumor\n[33](#B33) y ocasionar un incremento en la respuesta inmune dependiente de c\u00e9lulas Th1 [4](#B4). Tambi\u00e9n se ha observado que su bloqueo potencializa la producci\u00f3n de anticuerpos espec\u00edficos contra TAA, as\u00ed como una respuesta celular CD4+ y CD8+ ant\u00edgeno espec\u00edfica [27](#B27).\n2.5 PD-1\nPD-1 tambi\u00e9n es una prote\u00edna clave en la regulaci\u00f3n inmune\n[27](#B27), act\u00faa como un punto de control inmunol\u00f3gico y es un blanco inmuno-terap\u00e9utico. Es una mol\u00e9cula co-inhibitoria expresada en c\u00e9lulas T estimuladas, as\u00ed como en los linfocitos Treg, c\u00e9lulas B-activadas y c\u00e9lulas NK [27](#B27), [31](#B31). PD-1 parece tener una funci\u00f3n crucial en la modulaci\u00f3n de la actividad de las c\u00e9lulas T a trav\u00e9s de la interacci\u00f3n con sus ligandos PD-L1 y PD-L2 [31](#B31). PD-L1 se expresa en tejidos linfoides y no linfoides, es activado especialmente en APCs, DCs, macr\u00f3fagos y c\u00e9lulas B, aunque tambi\u00e9n se expresa en las c\u00e9lulas tumorales que abrogan la respuesta linfocitaria. La expresi\u00f3n de este ligando en el tejido tumoral es reconocida por los linfocitos T efectores, los cuales restringen su actividad oncol\u00edtica para inducir inmunotolerancia al c\u00e1ncer [24](#B24). PD-L2 solo se expresa en las APCs [24](#B24).\nDespu\u00e9s de la uni\u00f3n con su ligando, PD-1 suprime la activaci\u00f3n de c\u00e9lulas T reclutando SHP-2, la cual desfosforila e inactiva Zap70, un componente importante en la v\u00eda de se\u00f1alizaci\u00f3n del TCR. Como resultado, PD-1 inhibe la proliferaci\u00f3n de c\u00e9lulas T y sus funciones efectoras, como la producci\u00f3n de IFN-\u03b3\n[24](#B24). El bloqueo de PD-1 puede mejorar las respuestas inmunes antineopl\u00e1sicas al disminuir el n\u00famero y actividad supresora de las c\u00e9lulas Treg intratumorales [4](#B4), adem\u00e1s de incrementar la proliferaci\u00f3n de c\u00e9lulas T efectoras (CD8+/HLA-DR+/Ki67+c\u00e9lulas T), la producci\u00f3n del quimioatrayente alfa de c\u00e9lulas T inducible con interfer\u00f3n (I-TAC), de IFN-\u03b3 y de IL-18 [4](#B4).\n2.6 Interacciones entre CTLA-4 y PD-1\nAunque CTLA-4 y PD-1 regulan de manera negativa la activaci\u00f3n de las c\u00e9lulas T al bloquear la v\u00eda CD3/CD28, estos receptores tienen distintos papeles\n[27](#B27). CTLA-4 opera durante el inicio de la activaci\u00f3n de las c\u00e9lulas T nativas y de memoria en tejido linfoide y PD-1 opera durante la fase efectora de las c\u00e9lulas T [Fig. 3](/pmc/articles/PMC5687866/figure/f7/)\n[27](#B27), [34](#B34). La interacci\u00f3n de PD-1 con su ligando PD-L1 ocurre predominantemente en los tejidos perif\u00e9ricos, incluyendo el tejido tumoral [15](#B15), [27](#B27), [34](#B34).\nExisten estudios precl\u00ednicos que proponen una terapia combinada utilizando anticuerpos para el bloqueo simult\u00e1neo de ambas v\u00edas (anti-CTLA-4 m\u00e1s anti-PD-1)\n[12](#B12). Esta estrategia dual potenciar\u00eda la respuesta antitumoral, pero tambi\u00e9n se puede prever que resulte m\u00e1s t\u00f3xica [35](#B35).\n2.7 Uso cl\u00ednico del bloqueo de puntos de control inmunol\u00f3gicos\nEl ipilimumab (anti-CTLA-4) es un anticuerpo monoclonal recombinante humano (inmunoglobulina IgG1 kappa) aprobado por la Food and Drug Administration (FDA) en el 2011 para el tratamiento de melanoma metast\u00e1sico. El anticuerpo monoclonal humano nivolumab (anti-PD-1) es una inmunoglobulina IgG4 kappa autorizada en Jap\u00f3n en el 2014 para el tratamiento del melanoma no resecable. La FDA aprob\u00f3 el anticuerpo monoclonal humanizado pembrolizumab (inmunoglobulina IgG4 kappa) contra PD-1 en septiembre de 2014 y el nivolumab en diciembre de 2014, ambos para el tratamiento de melanomas avanzados. En marzo del 2015 la FDA aprob\u00f3 el nivolumab para el tratamiento de c\u00e1ncer de pulm\u00f3n\n[32](#B32).\nExisten estudios de fase II que muestran una mayor sobrevida en pacientes con melanoma metast\u00e1sico a los que se les administr\u00f3 ipilimumab\n[7](#B7), [36](#B36). En un estudio, se observ\u00f3 una sobrevida media de 10.1 meses en pacientes que usaron ipilimumab contra 6.4 meses en pacientes que usaron una vacuna pept\u00eddica control [36](#B36); tambi\u00e9n se observ\u00f3 una tasa de supervivencia en 5 a\u00f1os del 18.2% para pacientes con melanoma avanzado tratados con ipilimumab+dacarbazina contra el 8.8% de pacientes tratados con placebo+dacarbazina [37](#B37). Dos estudios fase III de nivolumab establecieron claros beneficios de este agente contra melanoma metast\u00e1sico en comparaci\u00f3n con la quimioterapia, mostrando una mejor tasa de supervivencia a un a\u00f1o [36](#B36). En julio del 2017, la compa\u00f1\u00eda Bristol-Myers Squibb anunci\u00f3 que la FDA expandi\u00f3 el uso de ipilimumab administrado de manera intravenosa como tratamiento para melanoma metast\u00e1sico no extirpable en pacientes pedi\u00e1tricos de 12 a\u00f1os de edad o mayores. As\u00ed mismo, en agosto del 2017, anunci\u00f3 que el nivolumab fue aprobado por la FDA para el tratamiento de pacientes adultos y pedi\u00e1tricos (mayores de 12 a\u00f1os) con c\u00e1ncer colorrectal metast\u00e1sico que presentan alta inestabilidad microsatelital (MSI-H) o deficiencia en la reparaci\u00f3n de errores en el DNA, en los pacientes refractarios al tratamiento con fluoropirimidinas, oxaliplatino e irinotecan. El pembrolizumab y el nivolumab (aprobados por la FDA) fueron comparados contra el ipilimumab, demostr\u00e1ndose una mayor respuesta y una menor toxicidad [36](#B36). Adem\u00e1s se observ\u00f3 que el bloqueo de PD-1 tuvo actividad en pacientes que no respondieron al bloqueo de CTLA-4 [36](#B36). Se ha propuesto que los agentes que inhiben PD-1 son m\u00e1s efectivos que los que inhiben directamente a PD-L1 (ej. anticuerpo monoclonal humano BMS-936559 [38](#B38), debido a que pueden inhibir ambos ligandos (PD-L1 y PD-L2) de manera simult\u00e1nea [38](#B38).\nEn 2015 se evalu\u00f3 la seguridad y eficiencia del nivolumab e ipilimumab por separado y en comparaci\u00f3n con una terapia combinada nivolumab + ipilimimab (registrado como CheckMate 067 en ClinicalTrials.gov), observ\u00e1ndose una sobrevida de 11.4 meses para el tratamiento combinado, contra con 6.9 meses para el tratamiento solo con nivolumab y 2.9 meses para el ipilimumab\n[39](#B39). Aunque se observa un aumento en la supervivencia de algunos meses, la inmunoterapia tiene un costo exorbitante; en el 2015 se estim\u00f3 un costo promedio por mg de $28.78 d\u00f3lares para el nivolumab, $51.79 d\u00f3lares para el pembrolizumab y $157.46 d\u00f3lares para el ipilimumab. Hay que considerar que las dosis de administraci\u00f3n van desde 2 mg/kg hasta 10 mg/kg cada 3 semanas, aproximadamente. Se calcula que el costo del tratamiento de un paciente con CheckMate 067 podr\u00eda ser de $295,566 d\u00f3lares; el del nivolumab de $103,220 d\u00f3lares y del ipilimumab de $158,252 d\u00f3lares. Teniendo en cuenta lo anterior, para un paciente de 75 kg con melanoma que recibe 26 de las dosis m\u00e1s altas y frecuentes de pembrolizumab, el costo del tratamiento ser\u00eda de $1,009,944 d\u00f3lares. Si el tratamiento se le proporcionara a cada uno de los 589,430 pacientes que mueren por c\u00e1ncer de melanoma anualmente, el costo para los sistemas de salud en general ser\u00eda de $173,881,850,000 d\u00f3lares. Esto es simplemente insostenible. Como en muchas otras \u00e1reas de la famacoeconom\u00eda de los medicamentos emergentes para las enfermedades cr\u00f3nicas, lo anterior representa un reto que debe resolverse considerando un equilibrio entre las demandas de la comunidad y de los sistemas de salud versus los intereses comerciales de los empresarios de las industrias farmac\u00e9uticas [40](#B40).\n2.8 Efectos adversos\nEl uso de ipilimumab y tremelimumab se ha asociado con eventos adversos que afectan la piel (prurito, vit\u00edligo), el intestino (diarrea y colitis), el h\u00edgado (hepatitis y enzimas hep\u00e1ticas elevadas) y las gl\u00e1ndulas end\u00f3crinas (hipotiroidismo, tiroidismo)\n[36](#B36). En comparaci\u00f3n con el bloqueo de CTLA-4, el bloqueo de PD-1 o PD-L1 puede tener efectos similares, pero parecen ser menos comunes [24](#B24), [36](#B36). Aunque se han mostrado buenos resultados en el uso de estas terapias, no son lo suficientemente efectivas para utilizarse solas [35](#B35), por lo que es necesaria su combinaci\u00f3n con otras estrategias. La terapia g\u00e9nica podr\u00eda ser una alternativa interesante para una terapia combinada.\n3. Terapia g\u00e9nica suicida\nLa selectividad terap\u00e9utica de los agentes antineopl\u00e1sicos es limitada, porque las c\u00e9lulas cancerosas son resistentes a la apoptosis, al arresto del ciclo celular y a la senescencia, adem\u00e1s que pueden emerger subpoblaciones celulares resistentes\n[41](#B41). La aplicaci\u00f3n de tecnolog\u00edas de terapia g\u00e9nica podr\u00eda mejorar la selectividad de las terapias dirigidas a los puntos de control inmunol\u00f3gico y facilitar el acceso de estas al tejido tumoral [42](#B42). La terapia suicida tiene dos alternativas: la terapia g\u00e9nica t\u00f3xica, en la cual se transducen genes para una prote\u00edna t\u00f3xica en las c\u00e9lulas tumorales, o la terapia de activaci\u00f3n enzim\u00e1tica de prof\u00e1rmacos. Esta \u00faltima consta de dos etapas: inicialmente, el gen de una enzima heter\u00f3loga es dirigido y entregado al tumor para su expresi\u00f3n. Posteriormente, se administra un prof\u00e1rmaco que es convertido en un medicamento citot\u00f3xico por la enzima heter\u00f3loga [43](#B43). Debido a su mecanismo de acci\u00f3n, esta terapia confiere una inmunorreactividad antitumoral, como se explicar\u00e1 m\u00e1s adelante.\nEl sistema HSV-TK/GCV es selectivo para las c\u00e9lulas tumorales debido a que afecta la replicaci\u00f3n activa del DNA de manera preferencial en las c\u00e9lulas tumorales, actividad que es baja en las c\u00e9lulas estromales circundantes, muchas de las cuales est\u00e1n en estado quiescente\n[42](#B42), [43](#B43).\n3.1 Enzimas y prof\u00e1rmacos usados en sistemas de terapia g\u00e9nica suicida\nLas enzimas utilizadas en terapia g\u00e9nica suicida se dividen en dos grupos. El primero comprende enzimas de origen no mam\u00edfero (ej. timidina quinasa del virus Herpes simplex [HSV-TK]. El segundo comprende enzimas de origen humano que est\u00e1n ausentes o se expresan a bajas concentraciones en c\u00e9lulas tumorales\n[43](#B43). Se han desarrollado varios sistemas enzima-prof\u00e1rmaco para terapia g\u00e9nica suicida, como los sistemas carboxil esterasa (CE)/irinotecan, carboxipeptidasa A (CPA)/p\u00e9ptidos MTX-a, carboxipeptidasa G2(CPG2)/CMDA y HSV-TK/ganciclovir (GCV). Este \u00faltimo sistema es el m\u00e1s estudiado y ha progresado exitosamente a ensayos cl\u00ednicos de fases avanzadas, por lo cual se explica con m\u00e1s detalle a continuaci\u00f3n [42](#B42), [44](#B44).\n3.2 Sistema HSV-TK/GCV\nEl sistema HSV-TK/GCV utiliza al ganciclovir y sus an\u00e1logos como prof\u00e1rmacos. Estos prof\u00e1rmacos son an\u00e1logos de los nucle\u00f3sidos de purina\n[5](#B5), [42](#B42). La administraci\u00f3n sist\u00e9mica del GCV induce apoptosis selectiva en las c\u00e9lulas transducidas con el gen TK. La HSV-TK es capaz de fosforilar el GCV, convirti\u00e9ndolo en GCV monofosforilado, que posteriormente es tri-fosforilado por quinasas celulares. Este producto bloquea la replicaci\u00f3n del DNA, causando adem\u00e1s su fragmentaci\u00f3n y apoptosis [45](#B45), [46](#B46)\n[Fig. 4](/pmc/articles/PMC5687866/figure/f8/).\nEl sistema HSV-TK/GCV se ha ensayado en estudios pre-cl\u00ednicos\n[47](#B47), [48](#B48) y cl\u00ednicos contra varios tipos de c\u00e1ncer, como tumores de pr\u00f3stata [49](#B49), [50](#B50), cerebro [51](#B51)- [53](#B53), ovario [54](#B54), [55](#B55), vejiga [56](#B56), [57](#B57), cuello uterino [58](#B58), p\u00e1ncreas [59](#B59), [60](#B60) y hep\u00e1tico [61](#B61), entre otros. Numerosos ensayos cl\u00ednicos de fase I y II han probado la seguridad y eficacia de esta terapia en humanos [43](#B43), [44](#B44). Diversos estudios demostraron que la transducci\u00f3n del gen HSV-TK es m\u00e1s segura y efectiva con vectores adenovirales de replicaci\u00f3n deficiente en comparaci\u00f3n con los vectores retrovirales [51](#B51), [62](#B62).\n3.3 Respuesta inmune inducida por el sistema AdV-TK/GCV.\nSe ha evidenciado que la terapia con HSV-TK/GCV induce inmunidad anti-tumoral\n[63](#B63), [64](#B64) e incluso, regresi\u00f3n de tumores cerebrales en ratas inmunocompetentes y de neuroblastoma en un modelo murino [65](#B65), [66](#B66). En los tumores tratados se observa una marcada infiltraci\u00f3n de c\u00e9lulas inflamatorias, con predominio de CD4+ y CD8+, lo que sugiere que el sistema HSV-TK/GCV estimula la respuesta inmune antitumoral [50](#B50), [60](#B60). Tambi\u00e9n se observa la sobreexpresi\u00f3n de las mol\u00e9culas coestimuladoras B7.1 y B7.2, mol\u00e9culas de adhesi\u00f3n intracelular (ICAM) y mol\u00e9culas del MHC en los tumores, y la atracci\u00f3n y activaci\u00f3n de APCs [67](#B67), [68](#B68).\nDurante el tratamiento de tumores con HSV-TK/GCV, se incrementan las citocinas que estimulan a las APCs y a las c\u00e9lulas T, como IL-2, IL-12, IFN\u03b3, TNF\u03b1 y GM-CSF, mientras que las citocinas inhibitorias IL-4, IL-6 e IL-10 no se estimulan\n[67](#B67). El incremento en la respuesta inmune ha sido demostrado por niveles m\u00e1s altos de c\u00e9lulas CD8 circulantes activas y por la elevaci\u00f3n de IL-12 en suero [69](#B69), [70](#B70), un mediador clave en la respuesta inmune celular contra infecciones virales y tumores malignos [69](#B69), [71](#B71). Los niveles de c\u00e9lulas NK se han relacionado con los niveles de IL-12, debido a que las c\u00e9lulas NK son uno de los blancos de acci\u00f3n de esta interleucina [69](#B69), [72](#B72).\nAdicionalmente, la prote\u00edna TK viral funciona como un s\u00faper-ant\u00edgeno, estimulando un microambiente tumoral altamente inmunog\u00e9nico\n[68](#B68). Esta prote\u00edna induce la liberaci\u00f3n y presentaci\u00f3n de TAAs que pueden ser reconocidos por los linfocitos T y generar una respuesta inmune adaptativa que tambi\u00e9n conduce a la cit\u00f3lisis de c\u00e9lulas tumorales y reclutamiento de APCs [68](#B68). Las APCs activadas inducen la proliferaci\u00f3n de c\u00e9lulas T por la secreci\u00f3n de IL-2 e IL-12 en el sitio del tumor. Todos estos eventos son deseables para conseguir un potente efecto anti-tumoral [73](#B73), [74](#B74). Sin embargo, debe considerarse una observaci\u00f3n que resulta contradictoria. Un ensayo cl\u00ednico de terapia neoadyuvate con HSV-TK/GCV para carcinoma pancre\u00e1tico mediada por un vector adenoviral, mostr\u00f3 niveles intratumorales incrementados de PD-L1 en espec\u00edmenes analizados despu\u00e9s de la resecci\u00f3n quir\u00fargica. Este evento puede disminuir la respuesta de las c\u00e9lulas T efectoras, pero puede revertirse con la co-administraci\u00f3n de inhibidores de PD-1/PD-L1 [60](#B60).\nLos ensayos cl\u00ednicos en los que se ha probado la terapia con HSV-TK/GCV mediada por vectores virales de manera \u00fanica o en combinaci\u00f3n con agentes quimioterap\u00e9uticos o radioterapia para c\u00e1ncer de pr\u00f3stata, carcinoma hepatocelular, o glioblastoma multiforme han mostrado progresos s\u00f3lidos hasta fase III\n[67](#B67), [68](#B68), [75](#B75).\n3.4 Efectos adversos\nA pesar de los resultados prometedores, existen algunas desventajas. Los vectores adenovirales deficientes en replicaci\u00f3n disparan una fuerte respuesta inmune humoral y celular que limita su duraci\u00f3n a un periodo de entre dos o tres semanas. A pesar de esto, estos vectores pueden resultar \u00fatiles para aplicaciones terap\u00e9uticas en los que un nivel muy alto de expresi\u00f3n transitoria del gen terap\u00e9utico es deseable, como ocurrir\u00eda en la terapia g\u00e9nica del c\u00e1ncer\n[76](#B76). Por otro lado, la expresi\u00f3n de la prote\u00edna TK no es espec\u00edfica de tumor. Una opci\u00f3n interesante es el uso de adenovirus que prefieran su replicaci\u00f3n en c\u00e9lulas tumorales usando un promotor espec\u00edfico [75](#B75).\nEn estudios en fase I y II se han mostrado algunos efectos secundarios, como fiebre leve, neutropenia, dolor de cabeza, trombocitopenia, alteraci\u00f3n de las enzimas hep\u00e1ticas, entre otros. Afortunadamente, estos eventos son transitorios y f\u00e1ciles de tolerar\n[49](#B49), [51](#B51), [62](#B62).\n4. Combinaci\u00f3n de terapias como nuevo tratamiento\nEl tratamiento combinado de terapia g\u00e9nica e inmunoterapia es una opci\u00f3n atractiva posibilitada por los avances recientes en la terap\u00e9utica del c\u00e1ncer. El empleo de un sistema de terapia g\u00e9nica suicida determinar\u00eda la presentaci\u00f3n s\u00fabita y masiva de TAAs por un periodo sostenido de semanas o meses. Resulta razonable pensar que esta terapia pueda ser reforzada de manera sin\u00e9rgica mediante su combinaci\u00f3n con un f\u00e1rmaco inhibidor de puntos de control inmunol\u00f3gico administrado de manera sist\u00e9mica como los descritos en esta revisi\u00f3n. Para ejemplificar m\u00e1s esta idea, se podr\u00eda suponer que un tumor tratado con HSV-TK/GCV generara la exposici\u00f3n s\u00fabita y masiva de TAAs al sistema inmune, los cuales en otras condiciones no generan una inmunoreactividad efectiva por la disminuci\u00f3n de MCH I y de mol\u00e9culas de coestimulaci\u00f3n y por la inducci\u00f3n de Treg. Este evento desencadenar\u00eda la atracci\u00f3n y activaci\u00f3n de las APC y se podr\u00eda esperar que algunos TAAs induzcan un incremento en el n\u00famero de linfocitos Treg intratumorales (incluso antes de la intervenci\u00f3n con terapia g\u00e9nica), propici\u00e1ndose un ambiente inmunosupresor. Para prevenir este fen\u00f3meno inmunol\u00f3gico y reforzar la respuesta antitumoral, la subsiguiente administraci\u00f3n de un inhibidor de punto de control inmunol\u00f3gico, por ejemplo un anticuerpo anti-PD1, afectar\u00eda la actividad de las c\u00e9lulas Treg intratumorales, lo que conducir\u00eda a un incremento en la proliferaci\u00f3n de las c\u00e9lulas T efectoras capaces de combatir al tumor y reforzar\u00eda una respuesta de memoria inmunol\u00f3gica que potencialmente tendr\u00eda un efecto protector de largo plazo\n[36](#B36).\nRecientemente se ensay\u00f3 un vector adenoviral portando el gen HSV-TK y la secuencia del dominio extracelular de PD-1 fusionada a la porci\u00f3n Fc de la IgG2a de rat\u00f3n, para producir el segmento PD-1 soluble (sPD1-Ig), que inhibe la actividad del ligando completo de manera competitiva, y por consecuencia, inhibe el efecto apopt\u00f3tico de las c\u00e9lulas T mediado por la interacci\u00f3n inmunosupresora del ligando \u00edntegro con su receptor. \u00c9ste se administr\u00f3 en un modelo murino de carcinoma de colon y demostr\u00f3 una sinergia entre la terapia HSV/TK y el bloqueo competitivo de la uni\u00f3n PD1/PD-L1. Hubo un decremento significativo en el volumen tumoral en el grupo de ratones tratados con HSV-TK/sPD1 en comparaci\u00f3n con los grupos controles, incluyendo el grupo de ratones tratados con el esquema simple HSV-TK/GCV\n[77](#B77).\nEs posible que en un futuro cercano se contin\u00faen realizando ensayos precl\u00ednicos y cl\u00ednicos que prueben hip\u00f3tesis similares a la que se plantea en este apartado y que seguramente tendr\u00e1n resultados cl\u00ednicos muy efectivos, y sobre todo, con un alto nivel de selectividad terap\u00e9utica, lo cual favorecer\u00e1 a\u00fan m\u00e1s el desarrollo de la medicina de precisi\u00f3n en el \u00e1rea de la oncolog\u00eda.\nConclusi\u00f3n\nLa potencializaci\u00f3n de la respuesta inmune contra los tumores podr\u00eda ser una estrategia clave para combatir el c\u00e1ncer. El sistema TK/GCV induce la presentaci\u00f3n masiva de TAAs de manera efectiva. Por otra parte, la expresi\u00f3n del s\u00faper-ant\u00edgeno TK facilita la inmunidad celular antitumoral. El uso de anticuerpos monoclonales contra puntos de control de la respuesta inmune, como CTLA-4 y PD-1, contrarrestan la inmunosupresi\u00f3n ocasionada por el tumor. Hasta ahora ambas estrategias se encuentran en ensayos cl\u00ednicos y han demostrado resultados prometedores. Se esperar\u00eda que la combinaci\u00f3n de estos dos tipos de terapias fuera sin\u00e9rgica, m\u00e1s selectiva y efectiva y que tuviera un efecto protector de largo plazo.", "language": null, "image": "https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0", "pagetype": "article", "links": ["#main-content", "https://www.ncbi.nlm.nih.gov/", "https://account.ncbi.nlm.nih.gov", "/myncbi/", "/myncbi/collections/bibliography/", "/account/settings/", "/account/signout/", "https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys", "https://www.ncbi.nlm.nih.gov", "/myncbi/", "#maincontent", "#", "/pmc/", "https://www.ncbi.nlm.nih.gov/pmc/advanced", "/pmc/about/userguide/", "/pmc/journals/", "/pmc/journals/2387/", "/pmc/issues/301638/", "/pmc/articles/PMC5687866/?report=reader", "/pmc/articles/PMC5687866/pdf/1657-9534-cm-48-03-00138.pdf", "#", "https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5687866%2F&text=Immunotherapy%20and%20gene%20therapy%20as%20novel%20treatments%20for%20cancer", "https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5687866%2F", "/pmc/journals/", "/pmc/journals/2387/", "/pmc/issues/301638/", "/pmc/about/disclaimer/", "/pmc/about/copyright/", "//doi.org/10.25100%2Fcm.v48i3.2997", "https://pubmed.ncbi.nlm.nih.gov/29213157", "#s1", "#", "#", "https://pubmed.ncbi.nlm.nih.gov/?term=Rangel-Sosa%20MM%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Aguilar-C\u00f3rdova%20E%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Rojas-Mart\u00ednez%20A%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Rangel-Sosa%20MM%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Aguilar-C\u00f3rdova%20E%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Rojas-Mart\u00ednez%20A%5BAuthor%5D", "#", "#", "#", "/pmc/about/disclaimer/", "mailto:dev@null", "/pmc/about/copyright/", "http://creativecommons.org/licenses/by/4.0/", "#B1", "#B2", "#B3", "#B4", "#B5", "#B6", "#B7", "#B8", "#B9", "#B7", "#B10", "#B10", "#B11", "#B10", "#B12", "#B13", "#B10", "#B13", "#B10", "#B10", "#B7", "#B14", "#B15", "#B14", "#B8", "#B16", "#B8", "#B17", "#B18", "#B18", "#B18", "#B19", "#B17", "#B8", "/pmc/articles/PMC5687866/figure/f1/", "#B18", "#B20", "#B20", "#B22", "#B20", "#B22", "#B20", "#B10", "#B20", "#B8", "#B20", "/pmc/articles/PMC5687866/figure/f1/", "/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=5687866_1657-9534-cm-48-03-00138-gf1.jpg", "/pmc/articles/PMC5687866/figure/f1/?report=objectonly", "/pmc/articles/PMC5687866/figure/f1/", "#B20", "#B4", "#B6", "#B15", "#B23", "#B24", "#B25", "#B23", "#B25", "#B4", "#B26", "#B27", "/pmc/articles/PMC5687866/table/t1/", "#B27", "#B26", "#B36", "#B80", "/pmc/articles/PMC5687866/table/t1/?report=objectonly", "#B28", "#B28", "#B12", "#B29", "#B4", "#B30", "#B4", "#B31", "#B4", "#B4", "/pmc/articles/PMC5687866/figure/f2/", "#B30", "#B30", "#B32", "/pmc/articles/PMC5687866/figure/f2/", "/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=5687866_1657-9534-cm-48-03-00138-gf2.jpg", "/pmc/articles/PMC5687866/figure/f2/?report=objectonly", "/pmc/articles/PMC5687866/figure/f2/", "#B31", "#B78", "#B79", "#B33", "#B4", "#B27", "#B27", "#B27", "#B31", "#B31", "#B24", "#B24", "#B24", "#B4", "#B4", "#B27", "/pmc/articles/PMC5687866/figure/f3/", "#B27", "#B34", "#B15", "#B27", "#B34", "/pmc/articles/PMC5687866/figure/f3/", "/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=5687866_1657-9534-cm-48-03-00138-gf3.jpg", "/pmc/articles/PMC5687866/figure/f3/?report=objectonly", "/pmc/articles/PMC5687866/figure/f3/", "#B34", "#B12", "#B35", "#B32", "#B7", "#B36", "#B36", "#B37", "#B36", "#B36", "#B36", "#B38", "#B38", "#B39", "#B40", "#B36", "#B24", "#B36", "#B35", "#B41", "#B42", "#B43", "#B42", "#B43", "#B43", "#B42", "#B44", "#B5", "#B42", "#B45", "#B46", "/pmc/articles/PMC5687866/figure/f4/", "/pmc/articles/PMC5687866/figure/f4/", "/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=5687866_1657-9534-cm-48-03-00138-gf4.jpg", "/pmc/articles/PMC5687866/figure/f4/?report=objectonly", "/pmc/articles/PMC5687866/figure/f4/", "#B47", "#B48", "#B49", "#B50", "#B51", "#B53", "#B54", "#B55", "#B56", "#B57", "#B58", "#B59", "#B60", "#B61", "#B43", "#B44", "#B51", "#B62", "#B63", "#B64", "#B65", "#B66", "#B50", "#B60", "#B67", "#B68", "#B67", "#B69", "#B70", "#B69", "#B71", "#B69", "#B72", "#B68", "#B68", "#B73", "#B74", "#B60", "#B67", "#B68", "#B75", "#B76", "#B75", "#B49", "#B51", "#B62", "#B36", "#B77", "https://scholar.google.com/scholar_lookup?title=Cancer+and+the+immune+system:+the+vital+connection&author=OK+Dzivenu&author=TJ+O'Donnell&publication_year=2003&", "/pmc/articles/PMC4085883/", "https://pubmed.ncbi.nlm.nih.gov/22918931", "https://scholar.google.com/scholar_lookup?journal=Ann+Oncol&title=Immuno-oncology+understanding+the+function+and+dysfunction+of+the+immune+system+in+cancer&author=O+Finn&volume=23&issue=Suppl+8&publication_year=2012&pages=viii6-viii9&pmid=22918931&", "/pmc/articles/PMC4684975/", "https://pubmed.ncbi.nlm.nih.gov/26548534", "https://scholar.google.com/scholar_lookup?journal=Mol+Oncol&title=Cancer+immunotherapy+Strategies+for+personalization+and+combinatorial+approaches&author=V+Sathyanarayanan&author=S+Neelapu&volume=9&issue=10&publication_year=2015&pages=2043-2053&pmid=26548534&", "/pmc/articles/PMC4856023/", "https://pubmed.ncbi.nlm.nih.gov/22437870", "https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Cancer&title=The+blockade+of+immune+checkpoints+in+cancer+immunotherapy&author=DM+Pardoll&volume=12&issue=4&publication_year=2012&pages=252-264&pmid=22437870&", "/pmc/articles/PMC4452068/", "https://pubmed.ncbi.nlm.nih.gov/26056594", "https://scholar.google.com/scholar_lookup?journal=Mol+Cell+Ther&title=Gene+therapy+for+cancer+present+status+and+future+perspective&author=MH+Amer&volume=2&publication_year=2014&pages=27-27&pmid=26056594&", "https://pubmed.ncbi.nlm.nih.gov/25818339", "https://scholar.google.com/scholar_lookup?journal=Semin+Cancer+Biol&title=Immune+evasion+in+cancer+Mechanistic+basis+and+therapeutic+strategies&author=DS+Vinay&author=EP+Ryan&author=G+Pawelec&author=WH+Talib&author=J+Stagg&volume=35&issue=Suppl&publication_year=2015&pages=S185-S198&pmid=25818339&", "/pmc/articles/PMC4492230/", "https://pubmed.ncbi.nlm.nih.gov/26069281", "https://scholar.google.com/scholar_lookup?journal=Oncologist&title=The+evolving+role+of+immune+checkpoint+inhibitors+in+cancer+treatment&author=GK+Pennock&author=LQ+Chow&volume=20&issue=7&publication_year=2015&pages=812-822&pmid=26069281&", "/pmc/articles/PMC4641952/", "https://pubmed.ncbi.nlm.nih.gov/26605342", "https://scholar.google.com/scholar_lookup?journal=J+Immunol+Res&title=Immune+checkpoint+modulation+in+colorectal+cancer+What&apos;s+new+and+what+to+expect&author=J+Jacobs&author=E+Smits&author=F+Lardon&author=P+Pauwels&author=V+Deschoolmeester&volume=2015&publication_year=2015&pages=158038-158038&pmid=26605342&", "/pmc/articles/PMC4388310/", "https://pubmed.ncbi.nlm.nih.gov/24531241", "https://scholar.google.com/scholar_lookup?journal=Curr+Opin+Immunol&title=New+insights+into+cancer+immunoediting+and+its+three+component+phases--elimination,+equilibrium+and+escape&author=D+Mittal&author=MM+Gubin&author=RD+Schreiber&author=MJ+Smyth&volume=27&publication_year=2014&pages=16-25&pmid=24531241&", "/pmc/articles/PMC5220497/", "https://pubmed.ncbi.nlm.nih.gov/28116316", "https://scholar.google.com/scholar_lookup?journal=J+Immunol+Res&title=The+immune+system+in+cancer+pathogenesis+Potential+therapeutic+approaches&author=PH+Pandya&author=ME+Murray&author=KE+Pollok&author=JL+Renbarger&volume=2016&publication_year=2016&pages=4273943-4273943&pmid=28116316&", "/pmc/articles/PMC2866629/", "https://pubmed.ncbi.nlm.nih.gov/20303878", "https://scholar.google.com/scholar_lookup?journal=Cell&title=Immunity,+inflammation,+and+cancer&author=SI+Grivennikov&author=FR+Greten&author=M+Karin&volume=140&issue=6&publication_year=2010&pages=883-899&pmid=20303878&", "/pmc/articles/PMC4746082/", "https://pubmed.ncbi.nlm.nih.gov/26834161", "https://scholar.google.com/scholar_lookup?journal=Oncologist&title=How+cancers+escape+immune+destruction+and+mechanisms+of+action+for+the+new+significantly+active+immune+therapies+Helping+nonimmunologists+decipher+recent+advances&author=JL+Messerschmidt&author=GC+Prendergast&author=GL+Messerschmidt&volume=21&issue=2&publication_year=2016&pages=233-243&pmid=26834161&", "/pmc/articles/PMC4788788/", "https://pubmed.ncbi.nlm.nih.gov/26967289", "https://scholar.google.com/scholar_lookup?journal=Cell&title=The+basis+of+oncoimmunology&author=AK+Palucka&author=LM+Coussens&volume=164&issue=6&publication_year=2016&pages=1233-1247&pmid=26967289&", "https://pubmed.ncbi.nlm.nih.gov/16557261", "https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Immunol&title=Regulatory+T+cells,+tumor+immunity+and+immunotherapy&author=W+Zou&volume=6&issue=4&publication_year=2006&pages=295-207&pmid=16557261&", "/pmc/articles/PMC4986235/", "https://pubmed.ncbi.nlm.nih.gov/27160722", "https://scholar.google.com/scholar_lookup?journal=Int+Immunol&title=Roles+of+regulatory+T+cells+in+cancer+immunity&author=Y+Takeuchi&author=H+Nishikawa&volume=28&issue=8&publication_year=2016&pages=401-409&pmid=27160722&", "https://pubmed.ncbi.nlm.nih.gov/24413387", "https://scholar.google.com/scholar_lookup?journal=Curr+Opin+Immunol&title=Regulatory+T+cells+in+cancer+immunotherapy&author=H+Nishikawa&author=S+Sakaguchi&volume=27&publication_year=2014&pages=1-7&pmid=24413387&", "/pmc/articles/PMC3530093/", "https://pubmed.ncbi.nlm.nih.gov/23199321", "https://scholar.google.com/scholar_lookup?journal=Clin+Exp+Immunol&title=Suppression,+subversion+and+escape+The+role+of+regulatory+T+cells+in+cancer+progression&author=K+Oleinika&author=RJ+Nibbs&author=GJ+Graham&author=AR+Fraser&volume=171&issue=1&publication_year=2013&pages=36-45&pmid=23199321&", "/pmc/articles/PMC3983433/", "https://pubmed.ncbi.nlm.nih.gov/24833840", "https://scholar.google.com/scholar_lookup?journal=World+J+Gastroenterol&title=Colorectal+cancer+and+immunity+What+we+know+and+perspectives&author=S+Pernot&author=M+Terme&author=T+Voron&author=O+Colussi&author=E+Marcheteau&volume=20&issue=14&publication_year=2014&pages=3738-3750&pmid=24833840&", "https://pubmed.ncbi.nlm.nih.gov/25519074", "https://scholar.google.com/scholar_lookup?journal=Expert+Opin+Investig+Drugs&title=The+potential+role+of+immunotherapy+to+treat+colorectal+cancer&author=M+Amin&author=AC+Lockhart&volume=24&issue=3&publication_year=2015&pages=329-344&", "/pmc/articles/PMC2665249/", "https://pubmed.ncbi.nlm.nih.gov/18566595", "https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Immunol&title=How+regulatory+T+cells+work&author=DA+Vignali&author=LW+Collison&author=CJ+Workman&volume=8&issue=7&publication_year=2008&pages=523-532&pmid=18566595&", "https://pubmed.ncbi.nlm.nih.gov/24276186", "https://scholar.google.com/scholar_lookup?journal=Gac+Med+Mex&title=Mecanismos+de+supresi\u00f3n+de+las+c\u00e9lulas+T+reguladoras+(Treg)&author=JM+Guzm\u00e1n-Flores&author=DP+Portales-P\u00e9rez&volume=149&publication_year=2013&pages=630-638&pmid=24276186&", "https://pubmed.ncbi.nlm.nih.gov/17762882", "https://scholar.google.com/scholar_lookup?journal=Cell+Death+Differ&title=Involvement+of+cellular+death+in+TRAIL/DR5-dependent+suppression+induced+by+CD4+CD25++regulatory+T+cells&author=X+Ren&author=F+Ye&author=Z+Jiang&author=Y+Chu&author=S+Xiong&volume=14&publication_year=2007&pages=2076-2084&pmid=17762882&", "/pmc/articles/PMC4980573/", "https://pubmed.ncbi.nlm.nih.gov/25605845", "https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&title=Immune+checkpoint+blockade+in+cancer+therapy&author=MA+Postow&author=MK+Callahan&author=JD+Wolchok&volume=33&issue=17&publication_year=2015&pages=1974-1982&pmid=25605845&", "/pmc/articles/PMC5381059/", "https://pubmed.ncbi.nlm.nih.gov/28376884", "https://scholar.google.com/scholar_lookup?journal=J+Biomed+Sci&title=Cancer+immunotherapies+targeting+the+PD-1+signaling+pathway&author=Y+Iwai&author=J+Hamanishi&author=K+Chamoto&author=T+Honjo&volume=24&issue=1&publication_year=2017&pages=26-26&pmid=28376884&", "/pmc/articles/PMC4289356/", "https://pubmed.ncbi.nlm.nih.gov/25606596", "https://scholar.google.com/scholar_lookup?journal=Arthritis+Res+Ther&title=Immune+checkpoint+receptors+in+regulating+immune+reactivity+in+rheumatic+disease&author=S+Ceeraz&author=EC+Nowak&author=CM+Burns&author=RJ+Noelle&volume=16&publication_year=2014&pages=469-469&pmid=25606596&", "https://pubmed.ncbi.nlm.nih.gov/28393361", "https://scholar.google.com/scholar_lookup?journal=Eur+J+Immunol&title=Immune+checkpoints+and+their+inhibition+in+cancer+and+infectious+diseases&author=L+Dyck&author=KHG+Mills&volume=47&issue=5&publication_year=2017&pages=765-779&pmid=28393361&", "/pmc/articles/PMC4717548/", "https://pubmed.ncbi.nlm.nih.gov/26788324", "https://scholar.google.com/scholar_lookup?journal=J+Immunother+Cancer&title=Novel+technologies+and+emerging+biomarkers+for+personalized+cancer+immunotherapy&author=J+Yuan&author=PS+Hegde&author=R+Clynes&author=PG+Foukas&author=A+Harari&volume=4&publication_year=2016&pages=3-3&pmid=26788324&", "https://pubmed.ncbi.nlm.nih.gov/19001145", "https://scholar.google.com/scholar_lookup?journal=Oncologist&title=The+mechanism+of+anti-CTLA-4+activity+and+the+negative+regulation+of+T-cell+activation&author=JD+Wolchok&author=Y+Saenger&volume=13&issue=Suppl+l4&publication_year=2008&pages=2-9&pmid=19001145&", "/pmc/articles/PMC3968368/", "https://pubmed.ncbi.nlm.nih.gov/24594636", "https://scholar.google.com/scholar_lookup?journal=Toxins&title=Immune+checkpoint+blockade+in+cancer+treatment:+A+double-edged+sword+cross-targeting+the+host+as+an+\"Innocent+bystander\"&author=L+Gelao&author=C+Criscitiello&author=A+Esposito&author=A+Goldhirsch&author=G+Curigliano&volume=6&issue=3&publication_year=2014&pages=914-933&pmid=24594636&", "/pmc/articles/PMC3559193/", "https://pubmed.ncbi.nlm.nih.gov/23390376", "https://scholar.google.com/scholar_lookup?journal=Cancer+Immun&title=CTLA-4+blockade+in+tumor+models+an+overview+of+preclinical+and+translational+research&author=JF+Grosso&author=MN+Jure-Kunkel&volume=13&publication_year=2013&pages=5-5&pmid=23390376&", "https://pubmed.ncbi.nlm.nih.gov/11905831", "https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Immunol&title=T-cell+regulation+by+CD28+and+CTLA-4&author=ML+Alegre&author=KA+Frauwirth&author=CB+Thompson&volume=1&issue=3&publication_year=2001&pages=220-228&pmid=11905831&", "https://pubmed.ncbi.nlm.nih.gov/26091825", "https://scholar.google.com/scholar_lookup?journal=Trends+Mol+Med&title=Checkpoint+blockade+for+cancer+therapy+revitalizing+a+suppressed+immune+system&author=Y+Pico+de+Coa\u00f1a&author=A+Choudhury&author=R+Kiessling&volume=21&issue=8&publication_year=2015&pages=482-491&pmid=26091825&", "/pmc/articles/PMC4400238/", "https://pubmed.ncbi.nlm.nih.gov/25858804", "https://scholar.google.com/scholar_lookup?journal=Cancer+Cell&title=Immune+checkpoint+blockade+A+common+denominator+approach+to+cancer+therapy&author=SL+Topalian&author=CG+Drake&author=DM+Pardoll&volume=27&issue=4&publication_year=2015&pages=450-461&pmid=25858804&", "https://pubmed.ncbi.nlm.nih.gov/24089443", "https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&title=CTLA-4+and+PD-1/PDL1+blockade+new+immunotherapeutic+modalities+with+durable+clinical+benefit+in+melanoma+patients&author=PA+Ott&author=FS+Hodi&author=C+Robert&volume=19&issue=19&publication_year=2013&pages=524-535&pmid=23231950&", "/pmc/articles/PMC4892769/", "https://pubmed.ncbi.nlm.nih.gov/26558876", "https://scholar.google.com/scholar_lookup?journal=Am+J+Clin+Oncol&title=CTLA-4+and+PD-1+pathways+Similarities,+differences,+and+implications+of+their+inhibition&author=EI+Buchbinder&author=A+Desai&volume=39&issue=1&publication_year=2016&pages=98-106&pmid=26558876&", "https://pubmed.ncbi.nlm.nih.gov/27192570", "https://scholar.google.com/scholar_lookup?journal=Immunity&title=Targeting+T+cell+co-receptors+for+cancer+therapy&author=MK+Callahan&author=MA+Postow&author=JD+Wolchok&volume=44&issue=5&publication_year=2016&pages=1069-1078&pmid=27192570&", "/pmc/articles/PMC5795709/", "https://pubmed.ncbi.nlm.nih.gov/25713437", "https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&title=Five-year+survival+rates+for+treatment-naive+patients+with+advanced+melanoma+who+received+ipilimumab+plus+dacarbazine+in+a+phase+III+trial&author=M+Maio&author=JJ+Grob&author=S+Aamdal&author=I+Bondarenko&author=C+Robert&volume=33&issue=10&publication_year=2015&pages=1191-1196&pmid=25713437&", "/pmc/articles/PMC4901122/", "https://pubmed.ncbi.nlm.nih.gov/26899259", "https://scholar.google.com/scholar_lookup?journal=Int+J+Clin+Oncol&title=PD-1/PD-L1+blockade+in+cancer+treatment+perspectives+and+issues&author=J+Hamanishi&author=M+Mandai&author=N+Matsumura&author=K+Abiko&author=T+Baba&volume=21&publication_year=2016&pages=462-473&pmid=26899259&", "https://pubmed.ncbi.nlm.nih.gov/26398076", "https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&title=Combined+nivolumab+and+ipilimumab+or+monotherapy+in+untreated+Melanoma&author=J+Larkin&author=FS+Hodi&author=JD+Wolchok&volume=373&issue=13&publication_year=2015&pages=1270-1271&", "/pmc/articles/PMC4570079/", "https://pubmed.ncbi.nlm.nih.gov/26380599", "https://scholar.google.com/scholar_lookup?journal=Am+Health+Drug+Benefits&title=Treating+with+checkpoint+inhibitor+Figure+$1+million+per+patient&author=A+Andrews&volume=8&publication_year=2015&pages=9-9&pmid=26380599&", "https://pubmed.ncbi.nlm.nih.gov/15077157", "https://scholar.google.com/scholar_lookup?journal=Oncogene&title=Prospective+strategies+to+enforce+selectively+cell+death+in+cancer+cells&author=MV+Blagosklonny&volume=23&issue=16&publication_year=2004&pages=2967-2975&pmid=15077157&", "/pmc/articles/PMC4758904/", "https://pubmed.ncbi.nlm.nih.gov/26004498", "https://scholar.google.com/scholar_lookup?journal=Adv+Drug+Deliv+Rev&title=Progress+and+problems+with+the+use+of+suicide+genes+for+targeted+cancer+therapy&author=Z+Karjoo&author=X+Chen&author=A+Hatefi&volume=99&issue=A&publication_year=2016&pages=113-128&pmid=26004498&", "/pmc/articles/PMC5423469/", "https://pubmed.ncbi.nlm.nih.gov/28548065", "https://scholar.google.com/scholar_lookup?journal=Biomedicines&title=Gene+therapy+used+in+cancer+treatment&author=T+Wirth&author=S+Yla-Herttuala&volume=2&issue=2&publication_year=2014&pages=149-162&pmid=28548065&", "https://pubmed.ncbi.nlm.nih.gov/15001663", "https://scholar.google.com/scholar_lookup?journal=Pharmacol+Rev&title=Enzyme-catalyzed+activation+of+anticancer+prodrugs&author=M+Rooseboom&author=JN+Commandeur&author=NP+Vermeulen&volume=56&issue=1&publication_year=2004&pages=53-02&pmid=15001663&", "/pmc/articles/PMC184786/", "https://pubmed.ncbi.nlm.nih.gov/6307132", "https://scholar.google.com/scholar_lookup?journal=Antimicrob+Agents+Chemother&title=Anti-herpesvirus+activity+of+the+acyclic+nucleoside+9-(1,3-dihydroxy-2-propoxymethyl)guanine&author=DF+Smee&author=JC+Martin&author=JP+Verheyden&author=TR+Matthews&volume=23&issue=5&publication_year=1983&pages=676-682&pmid=6307132&", "/pmc/articles/PMC5415956/", "https://pubmed.ncbi.nlm.nih.gov/28624190", "https://scholar.google.com/scholar_lookup?journal=Mol+Ther+Nucleic+Acids&title=Expression+of+Herpes+Simplex+Virus+thymidine+kinase/ganciclovir+by+RNA+trans-splicing+induces+selective+killing+of+HIV-producing+cells&author=CK+Ingemarsdotter&author=C+Poddar&author=C+Mercier&author=V+Patzel&author=AM+Lever&volume=7&publication_year=2017&pages=140-154&pmid=28624190&", "https://pubmed.ncbi.nlm.nih.gov/9917091", "https://scholar.google.com/scholar_lookup?journal=Cancer+Gene+Ther&title=Distribution,+persistency,+toxicity,+and+lack+of+replication+of+an+E1A-deficient+adenoviral+vector+after+intracardiac+delivery+in+the+cotton+rat&author=A+Rojas-Martinez&author=PR+Wyde&author=CA+Montgomery&author=SH+Chen&author=SL+Woo&volume=5&issue=6&publication_year=1998&pages=365-370&pmid=9917091&", "https://pubmed.ncbi.nlm.nih.gov/22634584", "https://scholar.google.com/scholar_lookup?journal=Cancer+Lett&title=Suicide+gene+therapy+in+cancer+where+do+we+stand+now?&author=S+Duarte&author=G+Carle&author=H+Faneca&author=MC+de+Lima&author=V+Pierrefite-Carle&volume=324&issue=2&publication_year=2012&pages=160-170&pmid=22634584&", "https://pubmed.ncbi.nlm.nih.gov/10340555", "https://scholar.google.com/scholar_lookup?journal=Hum+Gene+Ther&title=In+situ+gene+therapy+for+adenocarcinoma+of+the+prostate+a+phase+I+clinical+trial&author=JR+Herman&author=HL+Adler&author=E+Aguilar-Cordova&author=A+Rojas-Martinez&author=S+Woo&volume=10&issue=7&publication_year=1999&pages=1239-1249&pmid=10340555&", "/pmc/articles/PMC3842423/", "https://pubmed.ncbi.nlm.nih.gov/24052127", "https://scholar.google.com/scholar_lookup?journal=Cancer+Gene+Ther&title=Intraprostatic+distribution+and+long+term+follow-up+after+AdV-tk+++prodrug+as+neoadjuvant+to+surgery+in+patients+with+prostate+cancer&author=A+Rojas-Mart\u00ednez&author=AG+Manzanera&author=SW+Sukin&author=J+Esteban-Mar\u00eda&author=JF+Gonz\u00e1lez-Guerrero&volume=20&issue=11&publication_year=2013&pages=642-649&pmid=24052127&", "https://pubmed.ncbi.nlm.nih.gov/10933931", "https://scholar.google.com/scholar_lookup?journal=Mol+Ther&title=Phase+I+study+of+adenoviral+delivery+of+the+HSV-tk+gene+and+ganciclovir+administration+in+patients+with+recurrent+malignant+brain+tumors&author=TW+Trask&author=RP+Trask&author=E+Aguilar-C\u00f3rdova&author=HD+Shine&author=PR+Wyde&volume=1&issue=2&publication_year=2000&pages=195-103&pmid=10933931&", "https://pubmed.ncbi.nlm.nih.gov/24756350", "https://scholar.google.com/scholar_lookup?journal=J+Neurooncol&title=Prognostic+utility+of+gene+therapy+with+herpes+simplex+virus+thymidine+kinase+for+patients+with+high-grade+malignant+gliomas+a+systematic+review+and+meta-analysis&author=F+Zhao&author=J+Tian&author=L+An&author=K+Yang&volume=118&issue=2&publication_year=2014&pages=239-246&pmid=24756350&", "/pmc/articles/PMC4467037/", "https://pubmed.ncbi.nlm.nih.gov/26067671", "https://scholar.google.com/scholar_lookup?journal=PLoS+One&title=The+anti-tumor+effects+of+adipose+tissue+mesenchymal+stem+cell+transduced+with+HSV-TK+gene+on+U-87-driven+brain+tumor&author=SM+de+Melo&author=S+Bittencourt&author=EG+Ferrazoli&author=CS+da+Silva&author=FF+da+Cunha&volume=10&issue=6&publication_year=2015&pages=e0128922&pmid=26067671&", "https://pubmed.ncbi.nlm.nih.gov/11860538", "https://scholar.google.com/scholar_lookup?journal=Int+J+Gynecol+Cancer&title=Histologic+and+immunohistochemical+analysis+of+tissue+response+to+adenovirus-mediated+herpes+simplex+thymidine+kinase+gene+therapy+of+ovarian+cancer&author=A+Hasenburg&author=DC+Fischer&author=XW+Tong&author=A+Rojas-Mart\u00ednez&author=C+Nyberg-Hoffman&volume=12&issue=1&publication_year=2002&pages=66-73&pmid=11860538&", "/pmc/articles/PMC4440683/", "https://pubmed.ncbi.nlm.nih.gov/26005395", "https://scholar.google.com/scholar_lookup?journal=Gene+Ther+Mol+Biol&title=Adenoviral-delivered+HE4-HSV-tk+sensitizes+ovarian+cancer+cells+to+ganciclovir&author=JW+Rawlinson&author=K+Vaden&author=J+Hunsaker&author=DF+Miller&author=KP+Nephew&volume=15&publication_year=2013&pages=120-130&pmid=26005395&", "/pmc/articles/PMC2803447/", "https://pubmed.ncbi.nlm.nih.gov/20015348", "https://scholar.google.com/scholar_lookup?journal=J+Exp+Clin+Cancer+Res&title=A+novel+Bifidobacterium+infantis-mediated+TK/GCV+suicide+gene+therapy+system+exhibits+antitumor+activity+in+a+rat+model+of+bladder+cancer&author=W+Tang&author=Y+He&author=S+Zhou&author=Y+Ma&author=G+Liu&volume=28&issue=1&publication_year=2009&pages=155-155&pmid=20015348&", "https://pubmed.ncbi.nlm.nih.gov/24273940", "https://scholar.google.com/scholar_lookup?journal=Clin+Lab&title=Potent+antitumor+activity+of+the+combination+of+HSV-TK+and+endostatin+by+adeno-associated+virus+vector+for+bladder+cancer+in+vivo&author=JG+Pan&author=RQ+Luo&author=X+Zhou&author=RF+Han&author=GW+Zeng&volume=59&issue=9-10&publication_year=2013&pages=1147-1158&pmid=24273940&", "/pmc/articles/PMC2988757/", "https://pubmed.ncbi.nlm.nih.gov/21054886", "https://scholar.google.com/scholar_lookup?journal=BMC+Cancer&title=An+experimental+study+on+cervix+cancer+with+combination+of+HSV-TK/GCV+suicide+gene+therapy+system+and+Co+radiotherapy&author=D+Chen&author=Q+Tang&volume=10&publication_year=2010&pages=609-620&pmid=21054886&", "https://pubmed.ncbi.nlm.nih.gov/20599444", "https://scholar.google.com/scholar_lookup?journal=Biochim+Biophys+Acta&title=Cell+cycle+control+pathways+act+as+conditioning+factors+for+TK/GCV+sensitivity+in+pancreatic+cancer+cells&author=DD+Abate&author=LR+Garc\u00eda&author=L+Sumoy&author=C+Fillat&volume=1803&issue=10&publication_year=2010&pages=1175-1185&pmid=20599444&", "https://pubmed.ncbi.nlm.nih.gov/25795132", "https://scholar.google.com/scholar_lookup?journal=Cancer+Immunol+Immunother&title=Gene-mediated+cytotoxic+immunotherapy+as+adjuvant+to+surgery+or+chemoradiation+for+pancreatic+adenocarcinoma&author=LK+Aguilar&author=LA+Shirley&author=VM+Chung&author=CL+Marsh&author=J+Walker&volume=64&issue=6&publication_year=2015&pages=727-736&pmid=25795132&", "https://pubmed.ncbi.nlm.nih.gov/25073402", "https://scholar.google.com/scholar_lookup?journal=Pharmazie&title=Adenovirus+vector-mediated+herpes+simplex+virus-thymidine+kinase+gene/ganciclovir+system+exhibits+anti-tumor+effects+in+an+orthotopic+hepatocellular+carcinoma+model&author=R+Zhu&author=D+Chen&author=D+Lin&author=F+Lu&author=J+Yin&volume=69&issue=7&publication_year=2014&pages=547-552&pmid=25073402&", "/pmc/articles/PMC4826211/", "https://pubmed.ncbi.nlm.nih.gov/26716896", "https://scholar.google.com/scholar_lookup?journal=Oncotarget&title=Adenovirus-mediated+delivery+of+herpes+simplex+virus+thymidine+kinase+administration+improves+outcome+of+recurrent+high-grade+glioma&author=N+Ji&author=D+Weng&author=C+Liu&author=Z+Gu&author=S+Chen&volume=7&issue=4&publication_year=2016&pages=4369-4378&pmid=26716896&", "https://pubmed.ncbi.nlm.nih.gov/10854148", "https://scholar.google.com/scholar_lookup?journal=World+J+Urol&title=Prospects+for+herpes-simplex-virus+thymidine-kinase+and+cytokine+gene+transduction+as+immunomodulatory+gene+therapy+for+prostate+cancer&author=W+Hassan&author=MA+Sanford&author=SL+Woo&author=SH+Chen&author=SJ+Hall&volume=18&issue=2&publication_year=2000&pages=130-135&pmid=10854148&", "/pmc/articles/PMC4471533/", "https://pubmed.ncbi.nlm.nih.gov/26137259", "https://scholar.google.com/scholar_lookup?journal=Mol+Clin+Oncol&title=Enhanced+central+memory+cluster+of+differentiation+8++and+tumor+antigen-specific+T+cells+in+prostate+cancer+patients+receiving+repeated+in+situ+adenovirus-mediated+suicide+gene+therapy&author=M+Kubo&author=T+Satoh&author=KI+Tabata&author=H+Tsumura&author=M+Iwamura&volume=3&issue=3&publication_year=2015&pages=515-521&pmid=26137259&", "/pmc/articles/PMC43782/", "https://pubmed.ncbi.nlm.nih.gov/8183911", "https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+U+S+A&title=Development+of+anti-tumor+immunity+following+thymidine+kinase-mediated+killing+of+experimental+brain+tumors&author=D+Barba&author=J+Hardin&author=M+Sadelain&author=FH+Gage&volume=91&issue=10&publication_year=1994&pages=348-352&", "/pmc/articles/PMC2822245/", "https://pubmed.ncbi.nlm.nih.gov/14966351", "https://scholar.google.com/scholar_lookup?journal=J+Korean+Med+Sci&title=Bystander-mediated+regression+of+murine+neuroblastoma+via+retroviral+transfer+of+the+HSV-TK+gene&author=HS+Cho&author=HR+Lee&author=MK+Kim&volume=19&issue=1&publication_year=2004&pages=107-112&pmid=14966351&", "https://pubmed.ncbi.nlm.nih.gov/21465529", "https://scholar.google.com/scholar_lookup?journal=J+Cell+Biochem&title=Cytotoxic+immunotherapy+strategies+for+cancer+mechanisms+and+clinical+development&author=LK+Aguilar&author=BW+Guzik&author=E+Aguilar-Cordova&volume=112&publication_year=2011&pages=1969-1977&pmid=21465529&", "/pmc/articles/PMC4933478/", "https://pubmed.ncbi.nlm.nih.gov/26843484", "https://scholar.google.com/scholar_lookup?journal=Neuro+Oncol&title=Phase+II+multicenter+study+of+gene-mediated+cytotoxic+immunotherapy+as+adjuvant+to+surgical+resection+for+newly+diagnosed+malignant+glioma&author=LA+Wheeler&author=AG+Manzanera&author=SD+Bell&author=R+Cavaliere&author=JM+McGregor&volume=18&issue=8&publication_year=2016&pages=1137-1145&pmid=26843484&", "https://pubmed.ncbi.nlm.nih.gov/16480930", "https://scholar.google.com/scholar_lookup?journal=Mol+Ther&title=Biological+response+determinants+in+HSV-tk+++ganciclovir+gene+therapy+for+prostate+cancer&author=G+Ayala&author=T+Satoh&author=R+Li&author=M+Shalev&author=Y+Gdor&volume=13&issue=4&publication_year=2006&pages=716-728&pmid=16480930&", "/pmc/articles/PMC3129286/", "https://pubmed.ncbi.nlm.nih.gov/21738557", "https://scholar.google.com/scholar_lookup?journal=Future+Virol&title=Implications+of+the+innate+immune+response+to+adenovirus+and+adenoviral+vectors&author=SM+Gregory&author=SA+Nazir&author=JP+Metcalf&volume=6&issue=3&publication_year=2011&pages=357-374&pmid=21738557&", "/pmc/articles/PMC4151806/", "https://pubmed.ncbi.nlm.nih.gov/25051201", "https://scholar.google.com/scholar_lookup?journal=Int+J+Oncol&title=A+novel+cancer+vaccine+strategy+with+combined+IL-18+and+HSV-TK+gene+therapy+driven+by+the+hTERT+promoter+in+a+murine+colorectal+cancer+model&author=K+Higashi&author=S+Hazama&author=A+Araki&author=K+Yoshimura&author=N+Iizuka&volume=45&issue=4&publication_year=2014&pages=1412-1420&pmid=25051201&", "/pmc/articles/PMC5384344/", "https://pubmed.ncbi.nlm.nih.gov/28405496", "https://scholar.google.com/scholar_lookup?journal=Oncoimmunology&title=IL-12,+IL-15,+and+IL-18+pre-activated+NK+cells+target+resistant+T+cell+acute+lymphoblastic+leukemia+and+delay+leukemia+development+in+vivo&author=M+Boieri&author=A+Ulvmoen&author=A+Sudworth&author=C+Lendrem&author=M+Collin&volume=6&issue=3&publication_year=2017&pages=e1274478&pmid=28405496&", "https://pubmed.ncbi.nlm.nih.gov/9139853", "https://scholar.google.com/scholar_lookup?journal=Int+J+Cancer&title=Generation+of+an+anti-tumour+immune+response+in+a+non-immunogenic+tumour+HSVtk+killing+in+vivo+stimulates+a+mononuclear+cell+infiltrate+and+a+Th1-like+profile+of+intratumoural+cytokine+expression&author=RG+Vile&author=S+Castleden&author=J+Marshall&author=R+Camplejohn&author=C+Upton&volume=71&issue=2&publication_year=1997&pages=267-274&pmid=9139853&", "https://pubmed.ncbi.nlm.nih.gov/15638715", "https://scholar.google.com/scholar_lookup?journal=Curr+Gene+Ther&title=In+situ+gene+therapy+for+prostate+cancer&author=T+Satoh&author=A+Irie&author=S+Egawa&author=S+Baba&volume=5&issue=1&publication_year=2005&pages=111-119&pmid=15638715&", "/pmc/articles/PMC3983249/", "https://pubmed.ncbi.nlm.nih.gov/24722669", "https://scholar.google.com/scholar_lookup?journal=PLoS+One&title=A+systematic+comparison+of+the+anti-tumoural+activity+and+toxicity+of+the+three+Adv-TKs&author=Q+Gao&author=C+Chen&author=T+Ji&author=P+Wu&author=Z+Han&volume=9&issue=4&publication_year=2014&pages=e94050&pmid=24722669&", "https://pubmed.ncbi.nlm.nih.gov/12728277", "https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Genet&title=Progress+and+problems+with+the+use+of+viral+vectors+for+gene+therapy&author=CE+Thomas&author=A+Ehrhardt&author=MA+Kay&volume=4&publication_year=2003&pages=346-358&pmid=12728277&", "/pmc/articles/PMC3589170/", "https://pubmed.ncbi.nlm.nih.gov/23337984", "https://scholar.google.com/scholar_lookup?journal=Mol+Ther&title=Adenovirus+expressing+both+thymidine+kinase+and+soluble+PD1+enhances+antitumor+immunity+by+strengthening+CD8+T-cell+response&author=SP+Shin&author=HH+Seo&author=JH+Shin&author=HB+Park&author=DP+Lim&volume=21&issue=3&publication_year=2013&pages=688-695&pmid=23337984&", "/pmc/articles/PMC3786574/", "https://pubmed.ncbi.nlm.nih.gov/23470321", "https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Immunol&title=Molecular+mechanisms+of+T+cell+co-stimulation+and+co-inhibition&author=L+Chen&author=DB+Flies&volume=13&issue=4&publication_year=2013&pages=227-242&pmid=23470321&", "/pmc/articles/PMC4005613/", "https://pubmed.ncbi.nlm.nih.gov/23868869", "https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&title=Molecular+pathways+co-expression+of+immune+checkpoint+molecules:+signaling+pathways+and+implications+for+cancer+immunotherapy&author=CJ+Nirschl&author=CG+Drake&volume=19&issue=18&publication_year=2013&pages=4917-4924&pmid=23868869&", "http://clinicaltrials.gov", "#top", "//doi.org/10.25100%2Fcm.v48i3.2997", "#", "/pmc/about/disclaimer/", "/pmc/about/copyright/", "#B1", "#B2", "#B3", "#B4", "#B5", "#B6", "#B7", "#B8", "#B9", "#B7", "#B10", "#B10", "#B11", "#B10", "#B12", "#B13", "#B10", "#B13", "#B10", "#B10", "#B7", "#B14", "#B15", "#B14", "#B8", "#B16", "#B8", "#B17", "#B18", "#B18", "#B18", "#B19", "#B8", "/pmc/articles/PMC5687866/figure/f5/", "#B18", "#B20", "#B20", "#B22", "#B20", "#B10", "#B20", "#B8", "#B20", "/pmc/articles/PMC5687866/figure/f5/", "/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=5687866_1657-9534-cm-48-03-00138-gf5.jpg", "/pmc/articles/PMC5687866/figure/f5/?report=objectonly", "/pmc/articles/PMC5687866/figure/f5/", "#B20", "#B4", "#B6", "#B15", "#B23", "#B24", "#B25", "#B23", "#B25", "#B4", "#B26", "#B27", "/pmc/articles/PMC5687866/table/t2/", "#B27", "#B26", "#B36", "#B80", "/pmc/articles/PMC5687866/table/t2/?report=objectonly", "#B28", "#B28", "#B12", "#B29", "#B4", "#B30", "#B4", "#B31", "#B4", "/pmc/articles/PMC5687866/figure/f6/", "#B30", "#B30", "#B32", "/pmc/articles/PMC5687866/figure/f6/", "/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=5687866_1657-9534-cm-48-03-00138-gf6.jpg", "/pmc/articles/PMC5687866/figure/f6/?report=objectonly", "/pmc/articles/PMC5687866/figure/f6/", "#B31", "#B78", "#B79", "#B33", "#B4", "#B27", "#B27", "#B27", "#B31", "#B31", "#B24", "#B24", "#B24", "#B4", "#B4", "#B27", "/pmc/articles/PMC5687866/figure/f7/", "#B27", "#B34", "#B15", "#B27", "#B34", "/pmc/articles/PMC5687866/figure/f7/", "/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=5687866_1657-9534-cm-48-03-00138-gf7.jpg", "/pmc/articles/PMC5687866/figure/f7/?report=objectonly", "/pmc/articles/PMC5687866/figure/f7/", "#B34", "#B12", "#B35", "#B32", "#B7", "#B36", "#B36", "#B37", "#B36", "#B36", "#B36", "#B38", "#B38", "#B39", "#B40", "#B36", "#B24", "#B36", "#B35", "#B41", "#B42", "#B43", "#B42", "#B43", "#B43", "#B42", "#B44", "#B5", "#B42", "#B45", "#B46", "/pmc/articles/PMC5687866/figure/f8/", "/pmc/articles/PMC5687866/figure/f8/", "/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=5687866_1657-9534-cm-48-03-00138-gf8.jpg", "/pmc/articles/PMC5687866/figure/f8/?report=objectonly", "/pmc/articles/PMC5687866/figure/f8/", "#B47", "#B48", "#B49", "#B50", "#B51", "#B53", "#B54", "#B55", "#B56", "#B57", "#B58", "#B59", "#B60", "#B61", "#B43", "#B44", "#B51", "#B62", "#B63", "#B64", "#B65", "#B66", "#B50", "#B60", "#B67", "#B68", "#B67", "#B69", "#B70", "#B69", "#B71", "#B69", "#B72", "#B68", "#B68", "#B73", "#B74", "#B60", "#B67", "#B68", "#B75", "#B76", "#B75", "#B49", "#B51", "#B62", "#B36", "#B77", "/pmc/articles/PMC5687866/?report=reader", "/pmc/articles/PMC5687866/pdf/1657-9534-cm-48-03-00138.pdf", "#", "https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5687866%2F&text=Immunotherapy%20and%20gene%20therapy%20as%20novel%20treatments%20for%20cancer", "https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5687866%2F", "#", "https://twitter.com/ncbi", "https://www.facebook.com/ncbi.nlm", "https://www.linkedin.com/company/ncbinlm", "https://github.com/ncbi", "https://ncbiinsights.ncbi.nlm.nih.gov/", "https://www.nlm.nih.gov/socialmedia/index.html", "https://twitter.com/NLM_NIH", "https://www.facebook.com/nationallibraryofmedicine", "https://www.youtube.com/user/NLMNIH", "https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323", "https://www.nlm.nih.gov/web_policies.html", "https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office", "https://www.hhs.gov/vulnerability-disclosure-policy/index.html", "https://support.nlm.nih.gov/", "https://www.nlm.nih.gov/accessibility.html", "https://www.nlm.nih.gov/careers/careers.html", "//www.nlm.nih.gov/", "https://www.nih.gov/", "https://www.hhs.gov/", "https://www.usa.gov/"]}